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Non-alcoholic fatty liver disease (NAFLD) is a growing health problem in Western 
countries. Clinically bland steatosis (NAFL) and the more severe form of non-alcoholic 
steatohepatitis (NASH) have to be discriminated. The pathophysiological mechanisms 
responsible for the development and progression of NAFLD remain widely unclear. In 
clinical practice, the development of non-invasive diagnostic tools to differentiate 
between NAFL and NASH would be desirable for optimal follow-up and treatment of 
NAFLD patients. 
As microRNAs (miRNAs) are already used in different clinical settings for early disease 
detection and monitoring of disease progression, their potential to function as diagnostic 
tool for NAFLD was evaluated in human serum samples. In two independent human 
patient cohorts, the levels of four miRNAs were evaluated to find characteristic patterns. 
MiRNA 21 was found to be significantly different regulated in NASH patients only. As 
two other miRNAs with a known prognostic potential could be validated in our study, the 
diagnostic ability was evaluated in a combined approach. The combination of miRNA 
expression with apoptosis marker CK-18 fragment level in a simplified scoring system 
showed excellence in comparison to other prognostic tools such as the level of 
transaminases. 
In the second part of this study, the aim was to define miRNAs involved in the 
pathophysiological mechanisms of NAFLD. MiRNAs with characteristic expression 
patterns as well as potential target genes were investigated in a human biopsy cohort. 
Also, an in vitro model of human hepatocytes simulating the conditions of hepatic lipid 
accumulation and lipotoxicity was investigated to detect parallels in miRNA and target 
 
X 
gene expression patterns compared to patient samples. Expression of miR 223 and miR 
638 as well as of target genes JUN, FASN and PLIN5 in cultured cells showed 
similarities to human data.  
The significant difference in regulation of miRNA 122 between NAFL and NASH patient 
group indicates a potential regulative function of the miRNA in disease pathophysiology. 
A putative pathogenetic factor in disease development could be also the newly identified 
association between NAFLD and miRNA 638, which has a predicted key-role in the 
pathway of lipid accumulation. The inverse correlation of expression of the miRNA and 
its potential target gene Perilipin 5 suggests a regulatory interaction and is an important 






Die nicht-alkoholische Fettlebererkrankung (NAFLD) stellt eine zunehmende 
Gesundheitsgefährdung dar. Allgemein muss zwischen einfacher Steatose (NAFL) und 
der schwereren Form der Steatohepatitis (NASH) unterschieden werden. Die 
pathophysiologischen Mechanismen bei der Entstehung und Progression von NAFLD 
sind noch weitgehend ungeklärt. In der klinischen Praxis wird die Entwicklung von nicht-
invasiven diagnostischen Hilfsmitteln zur Unterscheidung zwischen NAFL und NASH 
angestrebt, um eine optimale Behandlung und Betreuung von NAFLD Patienten zu 
gewährleisten. 
Da MikroRNAs (miRNAs) bereits im Bereich der diagnostischen Erkennung als auch in 
der Überwachung von Krankheitsverläufen zur Anwendung kommen, wurde ihr Potential 
als diagnostisches Hilfsmittel im Serum von NAFLD Patienten untersucht. In zwei 
unabhängigen Patientengruppen wurde das Vorkommen von vier MikroRNAs auf 
mögliche charakteristische Muster hin untersucht. Im Serum der NASH Patienten konnte 
so eine signifikant höhere Konzentration von miR 21 nachgewiesen werden. Da zwei 
weitere miRNAs mit einem bereits bekannten prognostischen Potential durch die 
vorliegende Studie validiert werden konnten, wurde die Verwendung dieser drei miRNAs 
als diagnostischer Marker in einem kombinierten Ansatz überprüft: Die Verbindung der 
miRNA-Level mit dem Apoptosemarker CK-18 in einem vereinfachten 
Bewertungssystem stellte im Vergleich zu bekannten prognostischen Hilfsmitteln wie 
Serumtransaminasen eine Verbesserung dar. 
Ein weiteres Ziel dieser Studie war es, Assoziationen von miRNAs mit den 
pathophysiologischen Mechanismen von NAFLD zu definieren. Sowohl miRNAs mit 
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charakteristischen Expressionsmustern als auch deren potentielle Zielgene wurden in 
einer Kohorte aus humanen Leberbiopsien untersucht. In einem in vitro Model wurde 
versucht Parallelen von miRNA- und Zielgenexpression zu den Biopsieproben ausfindig 
zu machen, welche im Fall der miRNAs 223 und 638 sowie der Gene JUN, FASN und 
PLIN5 erfolgreich nachgewiesen werden konnten.  
Durch den neubeobachteten Unterschied in der Expression von miR 122 zwischen 
NASH und NAFL Patienten kann eine aktive regulatorische Rolle der miRNA in der 
Pathophysiologie von NAFLD angenommen werden. Ein potentieller Zusammenhang 
besteht auch zwischen der Manifestierung der Krankheit und der in dieser Studie neu 
mit ihr assoziierten miR 638, der eine Schlüsselrolle im Signalweg der 
Lipidakkumulation eingeräumt wird. Die inverse Korrelation der Expression der miRNA 
und ihrem potentiellen Zielgen PLIN5 geben Hinweis auf eine mögliche regulatorische 
Interaktion und sind eine wichtige Erkenntnis vor dem angestrebten Ziel, relevante 







1.1 The Metabolic Syndrome 
The metabolic syndrome (MetS) is defined as an accumulation of health risk factors 
for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). It is an 
increasing health problem worldwide1. The manifold factors include central obesity, 
elevated blood pressure, impaired glucose tolerance or dysglycemia, increased 
triglyceride levels and decreased high density lipoprotein (HDL) cholesterol levels. 
But also, the syndrome is associated with other clinical conditions besides from 
T2DM and CVD. Those include chronic low-grade inflammation, oxidative stress, 
hyperuricemia, hypertension, dyslipidemia, hyperandrogenism, hypogonadism and 
polycystic ovary syndrome, obstructive sleep apnea, vascular dementia and 
Alzheimer's disease, certain forms of cancer, hepatic steatosis and non-alcoholic 
fatty liver disease (NAFLD)2-4. The latter will be in the main focus of the following 
thesis. When Reaven first described the current paradigm of the MetS in 1988, he 
used the term Syndrome X, describing the interaction and relation between insulin 
resistance, hypertension, T2DM and CVD2. Up from then, many different terms 
found their way into medical literature, including the deadly quartet, the 
cardiometabolic syndrome, and the insulin resistance syndrome4. As MetS is a 
multifactorial disease summarizing always more than one component, there are 
many existing cutoffs for the thresholds in diagnostic parameters, which lead to the 
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condition that different medical boards have set up and established different criteria 
for MetS diagnosis during the last decades. Unaffected by these fine differences in 
the definition of diagnosis, it is a fact that a clustering of health factors for CVD, 
including obesity, has been observed and described already in the beginning of the 
20th century5. 
An epidemiological study recently published confirmed one third of the adult 
population of the USA is affected by MetS1. The syndrome is responsible for the 
majority of health care expenditures in the United States, which had the 
consequence to classify MetS to be more threatening to world health than acute 
infectious diseases as e. g. the human immunodeficiency virus (HIV) for developed 
countries6, 7. However, MetS is not just a problem of the obese population. For 
instance, 20 % of people with morbid obese (body mass index (BMI) > 40 kg/m2; > 
35 kg/m2 with comorbidities) health status have normal life spans and are, by 
definition, metabolically healthy8, 9. On the contrary, 40% of the population with 
normal BMI suffers from pathologies as hypertension, dyslipidemia, CVD and also 
NAFLD10, 11. These numbers show that MetS is not only caused by obesity, but still it 
remains the major health risk factor. 
 
1.2 Non-alcoholic fatty liver disease 
Fatty liver disease (FLD) is describing a broad spectrum of hepatic, metabolic as 
well as histological disorders and is characterized with a chronic and aberrant 




disorder are abusive consumption of alcohol (alcoholic fatty liver disease (ALD))12, 
an infection by genotype 3 hepatitis C virus or metabolic disorders which are 
associated with obesity. In particular, this metabolic manifestation is defined as non-
alcoholic fatty liver disease13. There is only little known about the pathophysiological 
background and the progression of NAFLD. Also, no reliable non-invasive diagnostic 
marker for the diagnosis of the different states of NAFLD has been defined. One key 
aspect of the work in hand is to investigate molecular factors triggering the 
manifestation and progression of NAFLD. The other is to evaluate potential 
biomarkers for non-alcoholic fatty liver disease in the context of the metabolic 
syndrome. The main focus for the two aims is on small non-coding ribonucleic acids 
(RNAs) – so-called microRNAs. 
 
1.2.1 Definition, epidemiology and natural course of NAFLD 
The term “NAFLD” is often used as a summary term in the context of other clinical 
terms and conditions: bland/simple steatosis or non-alcoholic fatty liver (NAFL), non-
alcoholic liver inflammation or non-alcoholic steatohepatitis (NASH) – many different 
names which may cause confusion in clinical practice as well as for patients. To 
avoid those and to set up diagnostic thresholds, the American Association for the 
Study of Liver Diseases (AASLD) established a diagnostic guideline. According to 
this, NAFLD diagnosis requires a primary accumulation of lipids with an exclusion of 
secondary causes for hepatic fat accumulation (e.g. extensive alcohol abuse, 
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steatogenic medication, viral infections and hereditary disorders)14. This lipid 
accumulation is also called hepatic steatosis and is defined as cytoplasmatic macro-, 
micro- or mixed vesicular incorporation of lipids within the hepatocytes15. In this 
condition medical literature coined the terms bland or simple steatosis or NAFL. If 
NAFL is progressing into inflammation and hepatocellular injury, it has to be 
separated as the more severe form of the disease, non-alcoholic steatohepatitis 
(NASH). By definition, NASH is a combination of primary steatosis and inflammation 
with hepatic injury; such is ballooning and necroapoptosis of hepatocytes. 
So summarized, the whole condition of NAFLD is separated into NAFL and NASH 
(see also Figure 1-1). 
The factor making NAFLD to a dangerous health condition is that NAFL patients 
might develop NASH, which leads to an increased risk to develop into fibrosis, 
cirrhosis and hepatocellular carcinoma (HCC)18, 19. These factors are causing a 
significant decrease in over-all survival for NASH patients (survival 70% versus 80%, 
mean observational interval 13.7 years) in comparison to a control population (risk 
factor adjusted) and to NAFL patients20, 21. 
NAFLD is an increasing epidemic health disorder in western countries. In Europe, it 
is the most common source of chronic liver disease22, 23. The prevalence is currently 
20% to 35% of adult population in developed countries, summiting in up to 50% of 
patients in the USA24, 25. At the same time NAFLD is gaining a health problem for 
children with an increasing prevalence ranging between 13% and 80%, which is 





Figure 1-1: Natural course and spectrum of NAFLD in total population (reproduced 
from14, 16, 17) 
It is well known that NAFLD is strongly associated with the risk factors of the 
metabolic syndrome which are addressed in chapter 1.2 of this work. The 
prevalence of obesity in NAFLD patients is between 30% and 100%, patients 
suffering from an additional T2DM are between 10% to 75%, still27. Assy et al. 
addressed in a study, that 50% of hyperlipidemia patients could be proven with 
hepatic fat infiltration by ultrasonography28. In another study, insulin resistance could 
be shown as a predictor for NASH (prevalence of 60%), evaluated in patients 
undergoing gastric bypass surgery29. As obesity is a well-established risk factor for 
NAFLD, characteristics of obese patients have been evaluated into depth. It has 
been shown that morbid obesity patients who are also undergoing bariatric surgery 
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are exceeding the level of 90% of NAFLD14; 12% of patients in this group were even 
suffering from advanced fibrosis in the liver30, 31. 
In the progression of NAFLD, 5% to 20% develop NASH; where-in 5% to 20% 
proceed into the development of fibrosis of higher grade. A small percentage (<5%) 
of those develop the clinical condition of a liver cirrhosis32. Estimations about the 
progression rates of NAFL patients into cirrhosis have also been performed; the 
calculated prevalence of NAFLD-cirrhosis in total population is between 0.05% and 
0.3%33. These numbers show that patients suffering from NAFLD carry an increased 
risk to develop severe liver disease. Remarkably, Ertle et al. found cases of HCC 
even in pre-cirrhotic livers, nevertheless highly correlated with the presence of 
advanced fibrosis and cirrhosis34. Following international estimations about the 
rapidly increasing numbers of NAFLD patients worldwide, it is already assumed, that 
NAFLD related HCC rate will also increase and will be doubled within the next 
decade35. 
Simplified, one can say that NASH patients have an elevated mortality rate; but 
NAFL patients do not14. 
Liver related mortality is on the third most common cause of death worldwide (13%) 
only exceeded by malignancies and CVD36. For obvious reasons the 
pathophysiological background as also the diagnostic methods deserve further 




1.2.2 Pathophysiology of NAFL and NASH 
The liver holds a central position in the context of glucose- and lipid-metabolism. The 
excess deposition and accumulation of lipid droplets in liver cells can cause adverse 
effects in the liver as well as in the whole organism. The physiological manifestation 
of NAFLD can be basically explained as an elevation of free fatty acid (FFA) inflow 
within the hepatocytes. 
The source of these FFA is an increase of hepatic de novo lipogenesis, an impaired 
lipid export out of the hepatocytes, an alteration of hepatic processing of dietary 
lipids delivered by lipoproteins or they are derived from insulin resistant adipose 
tissue37. As addressed under 1.2.1 in this work, a fraction of patients with bland 
steatosis proceed into the development of hepatocellular damage and inflammation 
defined as NASH. 
The most common paradigm describing the progression of NAFLD from simple 
steatosis to NASH is the ‘two-hit-hypothesis’ by Day et al. The ‘first hit’ described an 
imbalance of cellular lipid uptake or combustion, leading to hepatocellular lipid 
accumulation (NAFL). The imbalance between pro- and anti-inflammatory factors 
represents the ‘second hit’ which is defined by additional inflammation and leads to 
the development of NASH17. In Figure 1-1 those hits are also addressed. Bosserhoff 
and Hellerbrand extended Days’ paradigm by a ‘third hit’, which is defined by the 
imbalance of pro- and anti-fibrotic factors and leads into progressive hepatic fibrosis, 
ultimate cirrhosis and HCC16. 
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In the following, selected pathways and receptors involved in the pathophysiology of 
NAFLD will be introduced. A detailed discussion for selected genes of capital 
importance will be addressed later in this thesis in chapter 1.4. 
 
 
Figure 1-2: Relevant pathways in the development of NAFLD (reproduced from 38) 
The first interaction to mention in the context of MetS and NAFLD is the clear 
association with insulin resistance. In the majority of NAFLD patients an impaired 
insulin signaling is occurring. Both are described in the context of pathophysiology 




is one of its consequences38. Insulin is physiologically involved in lipogenesis and 
glucose uptake. When it comes to insulin resistance, the glucose uptake in the liver 
triggered by insulin is decreasing. Glucokinase activation is the major mechanism of 
insulin in glycolysis stimulation39. Insulin is also described as an activator for sterol 
regulatory element binding protein 1-c (SREBP-1c). This transcription factor is 
responsible for the stimulation of fatty acid synthase, acetyl-coenzyme A (CoA) 
carboxylase, liver pyruvate kinase and stearoyl-CoA desaturase; all known as key 
mediators in fatty acid synthesis40. The ability of insulin to increase lipogenesis might 
lead to the assumption that a resistance might cause an impaired fatty acid 
synthesis. However, it has been shown that in a state of high insulin resistance, 
insulins’ ability to activate SREBP-1c and promote lipogenesis is still active41, even 
when insulin is no longer able to decrease glucose production42. Insulin resistance in 
dysfunctional adipocytes is leading to an elevated level of released FFAs and taken 
up in distant tissues, such is the liver. An accumulation of triglyceride-derived toxic 
lipid metabolites within the hepatocytes and Kupffer cells is the consequence, which 
on their side again may cause an activation of inflammatory pathways43. 
The next important compartments to mention in this context are Peroxisome 
Proliferator-Activated Receptors (PPARs). PPARα, one of three known isoforms, is 
described as an important mediator in hepatic lipid balance. They can cause an 
increase of beta oxidation and are activated by fatty acid binding44. A correlation 
between the decrease of PPARα and an increase of NAFL has been published by 
Yeon et al45. The described activation of fatty acid beta oxidation can cause a 
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decrease in glucose uptake. This was shown in a study with diabetic patients and 
rodents, where PPARα overexpression caused an elevated glucose level46. The 
ability of PPARα to decrease plasma triglyceride levels largely by increasing 
triglyceride clearance, its role in regulating the availability of triglycerides for Very 
Low Density Lipoprotein (VLDL) secretion as well as the contribution in lowering 
tumor necrosis factor alpha (TNF-α) levels are all effects showing the contribution of 
PPARα to the pathophysiology of NAFLD47, 48. 
In the context of lipid absorption, it is important to mention the role of bile acids. 
These steroid acids synthesized by the liver are involved also in signaling and the 
uptake of fat soluble vitamins49. A critical role of bile acids is their function as a 
ligand for the Farnesoid X Receptor (FXR) which is involved in various inflammatory 
pathways, glucose and lipid homeostasis50, 51. It has been shown that FXR is similar 
to PPARα involved in activation of fatty acid beta oxidation. SREBP-1c, the 
transcription factor activated by insulin40, is inhibited by FXR - which may cause a 
downregulation of lipogenesis rates52. A study showed decreased expression of FXR 
in NAFLD patients, correlated with an increase of SREBP-1c and the Liver X 
receptor (LXR)53. In the context of NAFLD it is also important to clarify that FXR is 
playing a crucial role in antagonism of the nuclear factor kappa beta (NF-κB) 
signaling pathway, as this has been described to reduce hepatic inflammation54. 
These examples are showing the important role of FXR in the context of NAFLD, 





Liver X receptors are transcription factors involved in the control of lipid homeostasis 
by binding to specified LXR-response elements55. As cholesterol sensors, they are 
involved in the metabolism and absorption of sterols. A study described their 
promoting role in the development of NASH by an indirect activation of SREBP-1c56. 
Joseph et al. showed a direct involvement in regulation of lipid synthesis, by 
interacting with genes such as for instance fatty acid synthase (FAS)57.The direct 
connection of LXR to NAFLD has been already addressed above; a study has 
shown an increase of LXR correlated with an increase in SREBP-1c expression in 
the liver53. Former investigations could also demonstrate a connection between the 
redox state of the cell and LXR, specifically as a reaction partner in the oxysterol 
synthesis, which have an elevated level in NAFLD patients and act as important LXR 
activators58-60. First approaches about a reduction of reactive oxygen species 
production - another precursor unit of oxysterol synthesis - to reduce hepatic 
steatosis by decreasing the LXR level are currently under investigation. Only these 
few facts can already clarify the capital role LXR is playing in the pathophysiology of 
NAFLD. 
Another well-known receptor group in the context of NAFLD is the Pregnane X 
Receptor (PXR) family. Those classical hormone and xenobiotic receptors have 
been described in the context of metabolism and detoxification, specifically as 
stimulators of lipogenesis. Their high expression in the liver as well as the ability of 
decreasing fatty acid oxidation and gluconeogenesis is showing the important role in 
metabolism38, 61: The knockout of PXR in a diabetic mouse model causes an 
 
12 
inhibition of lipogenesis, an elevation in mitochondrial fatty acid beta-oxidation, an 
enhancement in insulin signaling and lower levels of inflammatory markers62. PXR 
represents another therapeutic target in the context of NAFLD; hence, developing 
and investigating potential agonists has already been started. 
As it has been addressed to be connected to numerous of the shown pathways and 
receptors, the role of SREBP-1c will be discussed in more detail in the following. 
Multiple interactions in the context of metabolism and NAFLD40, 41, 52, 53 are 
distinguishing its importance. Activated by insulin, SREBP-1c itself has an activating 
role at several points of the lipogenesis pathway. In several studies concerning 
SREBP-1c contribution in NAFLD, increased expression levels could be detected. 
An indirect cause of this is the upregulation of fatty acid oxidation by relieving the 
inhibition of one of its enhancing proteins, Forkhead box protein A263. An elevated 
rate of fatty acid beta-oxidation, an increase in lipogenesis as also the increase in 
mitochondrial reactive oxygen species production fit well the hypothesis that 
SREBP-1c is playing a key-role as activator and mediator in NAFLD which could 
also be shown in in vitro studies64, 65. 
These interactions are also promising factors to serve as targets in therapeutic 
approaches of SREBP-1c inhibition, leading to a potential prevention from liver 
steatosis and a decreased level of insulin resistance in a high-fat diet rodent 
model66. Pharmacologic modulation of SREBP-1c by the Japanese herbal ingredient 




decrease of the protein level also attenuated the progression from bland steatosis to 
NASH in mice67. 
To describe the complex network of involved pathways and receptors involved in the 
pathophysiology of NAFLD might go beyond the scope of this work. The selected 
samples give a glance about the close interaction between the main factors 
mediating the development of hepatic steatosis and steatohepatitis. 
 
1.2.3 NAFLD – consequences and prognosis  
To see the epidemiology and pathophysiology of NAFLD in the context of the entire 
organism, the following part will discuss the long-term outcomes as well as the intra- 
and extra-hepatic consequences of the disease. 
It has already been addressed earlier, that NAFLD patients have an elevated 
mortality rate. This can be specified by the fact, that NASH patients mortality is 
increased in comparison to NAFL patients, as a significantly higher rate of 
cardiovascular and hepatic complications was detected20, 21. The progression into 
NASH is always implicating the presence of inflammation and fibrosis, which is often 
leading into the development of cirrhosis and cancer, and therefore is correlating 
with an elevated mortality21. An insight into the systemic consequences of hepatic 
lipid accumulation could be gained in context of the affected pathways and receptors 
(1.2.2) with the major outcome of an impaired insulin sensitivity causing metabolic 
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complications and increasing the risk for cardiovascular and hepatic events. It has 
been shown that the liver is not only affected by MetS passively. In fact, the onset of 
steatohepatitis and associated insulin resistance are causing a menacing cycle. 
Even if the total number of patients developing an end-stage liver disease is 
proportionally low, extra-hepatic pathologies of the MetS will be enhanced anyway68. 
A close correlation between NAFLD and the inflammatory cascade of 
atherosclerosis has been investigated, as also a correlation to the onset of kidney 
and cardiovascular disease in the context of NAFLD was in the focus of numerous 
studies69. The issue whether insulin resistance is a consequence or a cause of 
NAFLD has already been addressed. The fact that the exceeded lipid content of liver 
cells is responsible for a reduction in insulin sensitivity in hyperinsulinemia is 
supporting the causal role of NAFLD, as this is described as a known symptom of 
pre-diabetes70. The outcome of several studies showing an earlier onset of steatosis 
and insulin resistance in liver tissue compared to peripheral insulin resistance also 
points towards a primary causal effect of NAFLD in the development of T2DM and 
the MetS71, 72. 
 
1.2.4 Diagnosis of NASH versus NAFL 
The differential diagnosis of NAFLD is a critical challenge. The most important step 
within the diagnostic pathway is the assessment of patients’ alcohol consumption. It 
is crucial to detect prior or active consumption of relevant amounts of alcohol intake. 




alcoholic fatty liver disease and alcoholic steatohepatitis (ASH) is always a risk. 
There are different thresholds for the amount of alcohol intake defined as 
hepatotoxic. The recommendations of the AASLD define >210 grams in average per 
week in men and >140 grams in average in women as the threshold for significant 
alcohol intake in clinical practice14, whereas these values should be seen in a two-
year timeframe before consultation and diagnosis. 
Overall, one can say that all individuals suffering from obesity or any other 
manifestations of the Mets should be screened for NAFLD. But NAFLD is not 
restricted to these patients. Also individuals showing no symptoms in these 
pathologies have been detected with severe hepatic lipid accumulations.  
Most NAFLD patients are asymptotic; however, sometimes symptoms as pressure in 
the epigastric area or elevated lassitude appear. As shown in Figure 1-3, in the most 
cases, the disease is detected by routine blood tests. A persistent elevation of liver 
enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) is usually the first sign for a NAFLD manifestation and can be detected in 80% 
of NASH patients and in 50% of NAFL patients73, 74. It is also possible to detect liver 
steatosis by ultrasound in a clinical routine examination by an enhanced 
echogenicity. As it has been addressed earlier in concern of the alcohol 
consumption, an in-depth anamnesis is crucial. First of all, all other causes of liver 
diseases, causing elevated liver enzymes or hepatic steatosis should be evaluated 
and excluded. Examples could be medications or toxins, inflammatory or 
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autoimmune diseases, lipodystrophy and malnutrition, but also viral hepatitis should 
be taken into consideration. A next step would be the consideration of risk factors 
(as shown in Figure 1-3) making NAFLD more likely (e.g. T2DM and impaired 
glucose tolerance, obesity, hyperuricemia, arterial hypertension, 
hypertriglyceridemia and hypercholesterolaemia)37. 
In routine laboratory investigation the focus is on transaminase detection first. It is 
important to mention that serum transaminase levels will not infrequently be within 
the normal range in NAFLD patients; a problem strongly associated with one of the 
basic questions of this project. It also has to be mentioned that other serum 
parameters, such as ɣ-glutamyltransferase (GGT), cholinesterase or ferritin might be 
elevated as well, and also normal readings in laboratory chemistry do not totally 
exclude liver disease or even cirrhosis, as also some parameters are ‘re-normalized’ 
during the progression into NASH75. All this leads to the conclusion that the 
diagnosis of NAFLD by routine parameters is not reaching satisfying performance 
levels. This statement is based on the consideration of sensitivity, specificity and the 
discrimination from other liver diseases and follows the recommendations of the 
AASLD14, 37. 
For diagnosis of hepatic steatosis, without differentiating between NAFL, NASH and 
even early cirrhosis76, ultrasonography is the current gold standard77. Also computed 
tomography’s potential is in detection of steatosis, but is lacking the ability of 
differentiation. As a rather costly alternative with the additional patients risk due to 




costal factor, the limited availability as well as the restricted ability of ultimate 
discrimination also holds true for magnetic resonance imaging78. 
FibroScan is also a method to access the status of liver fibrosis by detecting the 
hepatic stiffness level. It is also described as transient elastography and has been 
established in a wide spectrum of liver diseases. The principle is simple, measuring 
the degree of fibrosis by ultrasound. Recent studies have shown correlations 
between FibroScan results and histological results, so an exclusion or diagnosis of 
advanced severe fibrosis, detectable in the progression from NASH into cirrhosis is 
possible79. Recent developments enable the non-invasive quantification of liver fat 
by shear wave elastography (Fibroscan CAP system) in selected centers80-83. 
It has been stated that already the diagnosis of NAFLD is challenging. In clinical 
routine the more crucial diagnostic decision is the discrimination between bland 
steatosis and steatohepatitis. The definition of non-invasive serum markers is one of 
the major aims of the thesis in hand and will be discussed more detailed later in this 
chapter as well as under 3 First manuscript. In the following current approaches in 
NASH diagnosis will be addressed first. 
The terms of NAFL and NASH are sometimes not exactly discriminated, which may 
cause confusion in clinical routine. The guidelines of the AASLD define that NAFLD 
is requiring the presence of primary hepatic steatosis14. This should be diagnosed 
via imaging or by histology. Also, reasons for secondary hepatic fat accumulation, 
such as steatogenic medication, virus infection or alcohol abuse should be excluded, 
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as it has been discussed in detail under 1.2.2. Primary hepatic steatosis is 
associated with cytoplasmic micro-, macro or mixed vesicular incorporation of lipids 
in the hepatocytes (NAFL)15. The progression of NAFL usually comes in form of 
bacterial translocation or elevated levels of pathogen-associated molecular patterns 
(PAMPs) in the portal vein and causes steatohepatitis84. 
The gold standard in NASH diagnosis in clinical practice to differentiate between 
NAFL and NASH is the histological examination of a piece of liver tissue (liver 
biopsy) as shown in Figure 1-3. Liver biopsy is usually performed through the skin 
under ultrasound guidance85-87. It involves taking a small liver section using a sharp 
hollow needle. This can be performed under local anesthesia85-87. Percutaneous 
biopsy bears an increased risk for patients health, as it can cause clinical significant 
bleeding (1.1-1.6%)85, 86, which might be fatal86. The high prevalence of MetS in the 
population is making it unrealistic to apply the invasive procedure to all individuals at 
risk for a NAFLD manifestation. Even if liver biopsies are to date the only possibility 
to evaluate liver pathology, they are only reflecting the situation at a certain point of 
time. Furthermore, in-depth anamnesis of individuals remains crucial, to discriminate 





Figure 1-3. Management of fatty liver disease diagnosis (reproduced from 89, 90) 
 
Taken together, by considering the risks and efforts linked to liver biopsies and the 
limited opportunities for the discrimination between ‘simple’ steatosis and 
steatohepatitis for the described imaging technologies - the development of non-
invasive diagnostic tools to differentiate between NAFL and NASH remains crucial 
for optimal follow-up and treatment of NAFLD patients. 
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Alternative methods for NASH diagnosis have also been under investigation. A 
recently published breath test study investigated the compounds of volatile organic 
material in exhaled air to diagnose the presence of NASH. The procedure based on 
gas chromatography - mass spectrometry analysis, could show a significant number 
of additionally diagnosed NASH patients and could decrease the number of liver 
biopsies without necessity91. 
Nevertheless, the current focus in NASH diagnosis still remains on the 
establishment of non-invasive blood biomarkers. A main attribute of steatohepatitis 
is the increase of apoptosis of liver cells. During liver cell apoptosis, cytokeratin-18 
(CK-18), an intermediary filament protein expressed by hepatocytes is which is 
proteolytically cleaved by caspases92, 93. The resultant CK-18 fragments are 
released in patients’ blood by the hepatocytes and can be detected in serum by 
specific monoclonal CK-18-antibody M30 in an Enzyme-linked Immunosorbent 
assay (ELISA)94. CK-18 fragments are one of the most promising biomarkers for 
NASH diagnosis – one reason, why it has been in a special focus in the 
experimental part of the work in hand. Its appearance could also be correlated with 
histological progression of NAFLD77. However, the sensitivity and positive predictive 
value for NASH is low95 and the AASLD practice guideline describes CK-18 
fragments as a marker with a high potential, but not recommended as solid marker 
for differentiation between NAFL and NASH14. The search for reliable non-invasive 
biomarkers is still ongoing. Potential candidates, such as the interleukin 1 receptor 




clear trend of upregulation during the progression of NAFLD could be shown, but still 
lacking on satisfying results in terms of NASH discrimination from NAFL96. 
Numerous other approaches have been investigated – fibroblast growth factor 21, 
TNF-α and other promising inflammatory markers – but the diagnostic performance 
and validation in independent cohorts have not lead to satisfying outcomes. One 
problem could be that other organs suffering from MetS are affected by inflammatory 
reactions also, which might be reflected by blood serum levels. In recently published 
studies the diagnostic potential of microRNAs, small RNAs of 19 to 23 nucleotides in 
total length regulating gene expression and usually acting at posttranscriptional 
level, have been investigated. These miRNAs, usually evaluated in cell free plasma 
or serum are also called circulating miRNAs. The range of miRNA applications is 
getting broader as they are used in different clinical settings for early disease 
detection and monitoring of disease progression97. The advantage of circulating 
miRNAs is obvious, as they give a less invasive opportunity to describe the 
physiological as well as the potential pathological state of their origin organ/ tissue. 
Very recently, Pirola et al. made an attractive approach by using miRNAs as 
potential diagnostic markers for the assessment of NAFLD97. The pooling of CK-18 
and fibroblast growth factor 21 levels also increased specificity and sensitivity of 
NASH diagnosis98, 99. The combined knowledge of these approaches have put the 
basis for one main part on the experimental setting of this work, as the combination 
of miRNA expression level with CK-18 fragment level have been investigated in the 
first part of the project ‘Performance of Serum microRNAs -122, -192 and -21 as 
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Biomarkers in Patients with Non-Alcoholic Steatohepatitis’ (see 3 First Manuscript). 
The diagnostic performance of acquired results had promising potential. However, to 
achieve a broad clinical application, the further investigation and improvement of 
NASH biomarkers remains crucial98. 
 
1.2.5 Treatment options 
After a successful diagnosis of NAFLD, respectively NASH or NAFL, there are 
different treatment options. The main therapeutic goal is the prevention or at least 
deceleration of the disease progression, which means in case of steatosis 
prevention of NASH development, and – in case of steatohepatitis onset – to avoid 
progression of fibrosis and cirrhosis. However, the focus is not only the containment 
of the manifestations within the liver, but also the risk factors of the metabolic 
syndrome; such are insulin resistance and obesity. Following this paradigm, the 
modification of patients’ lifestyle comes to the fore.  
Weight loss, achieved by physical training or the change of food habits is usually 
changing the progression of fatty liver disease. A reduction of hepatic insulin 
resistance, adipose tissue and serum ALT is an often observed consequence100. 
Usually the elimination of unfavorable co-factors, e.g. alcohol or drugs with elevated 
hepatotoxicity, is also recommended. 
If a reduction of weight cannot be achieved by the described measures or if the BMI 




due to severe illness, bariatric surgery is taken into consideration in an increasing 
number of cases. It has been shown, that in these patients the long term weight loss 
lead to a decreased level of hepatic fat accumulation. Analysis of bariatric patients 
showed also a decrease in mortality, morbidity and in detected cancers101. However, 
bariatric surgery is not a standard treatment of NAFLD patients yet, but the obtained 
achievements considering the reduction of steatosis, fibrosis as well as inflammation 
should be further investigated under the light of the prevention of NAFLD 
progression into cirrhosis102. 
In the last years, different approaches for drug based NAFLD treatments have been 
investigated. Metformin, one of the first line treatment options for pre-diabetics and 
T2DM patients, could not be proven to have any significant effect on steatosis. 
Neither histology nor transaminases showed an improvement compared to changes 
in lifestyle19. Pioglitazone, a PPAR-ɣ agonist showed positive effects by improving 
the status of inflammation and steatosis103, 104. For further evaluation, broad studies 
about long-term effects and the effect on fibrosis have to be conducted14, 19, 105. 
However, safety concerns regarding an increased risk of cardiovascular events 
remain and it is important to mention that these drugs are only licensed for diabetic 
patients.  
Hepatic cell injury in NASH context is often referred to in the same line with oxidative 
stress. Hence, the impact of the antioxidant vitamin E is also in the focus of 
investigation for NASH treatment options. Randomized studies showed improvement 
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in inflammation and steatosis, whereas no effect on fibrosis could be proven104. 
Again, safety concerns regarding an increased risk of cancer prevail and clinical 
evidence only exists for non-diabetic patients. 
An advanced degree of necroinflammation and fibrosis is often correlated with a 
deficient incidence of the secosteroid vitamin D in NAFLD patients106. The fact that it 
has been proven to play a relevant role in cancers as also in infectious and 
autoimmune diseases, where anti-inflammatory effects could be shown107, makes it 
to a substance of interest in NASH therapy. It is currently investigated in further 
studies and remains a therapeutic opportunity with high potential108. 
 
1.3 MicroRNAs 
Since microRNAs (miRNAs) have been discovered in 1993109, scientists proofed a 
regulative function in various gene expression pathways. 
These small RNAs of 19 to 23 nucleotides in total length regulate gene expression 
acting usually at posttranscriptional level. In majority (80%), their sequence is 
located in non-coding intronic sections of the genome110, 111, where they can be 
found either as clusters of genes or as single genes, controlled by the promotor of 
the protein coding genes or by their own promotors112. They are involved in 
regulating the activity of thousands of genes and their protein synthesis113. MiRNAs 
are very stable in clinical samples as they are resistant to the degradation by 




attractive diagnostic tools for less invasive distinguishing of patient’s health status114, 
a fact, also bringing them in the focus of the study design of the work in hand. These 
miRNAs, usually evaluated in cell free plasma or serum are also called circulating 
miRNAs. The range of miRNA applications is getting broader as they are used in 
different clinical settings for early disease detection and monitoring of disease 
progression97; and - as they have been linked to a number of different diseases - 
also the first miRNA based therapy options are under investigation115. 
A microRNA specific database (http://www.mirbase.org) list over 28645 entries and 
associated publications and is steadily growing116. 
 
1.3.1 MiRNAs - An introduction 
MicroRNAs are to date estimated to regulate more than 30% of the protein-coding 
genome in humans117. These small molecules are recognized today as key 
mediators in cellular processes, including cellular differentiation and -growth, 
proliferation as well as apoptosis118, 119. As shown in Figure 1-4, miRNAs are most 
commonly processed by RNA polymerase II, but also occasionally RNA polymerase 
III is responsible for transcription. The products are the long hairpin precursor 
structures called pri-miRNA120, 121. These precursors are poly-adenylated (3’ end) 
and capped (5’ end), just as other protein coding primary transcripts122-124. Their 
unique hairpin structure helps the microRNA specific biogenesis apparatus to 
separate them from other RNA stem loop-like structures in the nucleus121. The 
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processing pathway is canonical, where the pri-miRNA is going through a two-step 
mechanism which involves ribonuclease (RNase) III-family proteins Drosha and 
Dicer125, 126. This has the consequence that the newly synthesized pri-miRNA is 
cleaved by the nuclear Drosha, which forms, supported by its cofactor DGCR8 
(DiGeorge syndrome chromosomal [or critical] region 8) the microprocessor complex 
for export from the nucleus by the nuclear export factor exportin 5 (Exp5)127, 128. 
MicroRNAs general function is acting as imperfect sequence guides to recruit a 
ribonucleoprotein (RNP) complex to the complementary RNA. By the usage of this 
paradigm, they act in a familiar manner to other RNP components, in particular by 
providing a binding component which is sequence-specific. This allows the RNP to 
act on a particular target129. This function is working with the same concept as 
messenger RNA (mRNA) splicing. Small nuclear RNAs are bound to corresponding 
proteins building a RNP (snRNP) which introduces splicing.129, 130 
The miRNA-RNP complex is defined as RNA-induced silencing complex (RISC) and 
is using the miRNA to build a sequence specific complex with target mRNA. The 
complementary sequence is often between seven and eight bases. It is important to 
mention that longer stretches of complementarity might even enhance binding. The 
complementary sections of the miRNA and its target are preferentially located at the 
5’ end of the miRNA, which is also called the seed (nucleotides 2-8 counted from 5’ 
end)117. If the complementarity at the 6-mer site is from nucleotides 2-7, it is usually 
not sufficient for the repression of the target mRNA, but an additional complement 




Altogether, there are five different classes of miRNA binding sites: 
- Class I: Binding only relies on the seed 
- Class II: Seed bind and complementarity in nucleotides 13-16 
- Class III: Seed bind and complementarity in nucleotides 17-21 
- Class IV: No seed binding, but resemble centered binding (nucleotides 9-16) 
- Class V: Distributed or less stable binding 
(Adapted from 133) 
The RISC induced complex is often used in context with the term of gene silencing. 
This might give a wrong expression, as in most of the cases the result is not a total 
gene silencing, but more a regulating mechanism in the calibration of gene 
expression129. 
MiRNAs can direct the repression of target genes, which makes them not only 
conceptually, but also mechanistically related to RNA interference (RNAi) and small 
interfering RNA (siRNA). The mechanism of repression usually differs between 
different binding areas on the miRNA seed- and central region (nucleotides 2-12 of 
the miR). Generalized, if miRNA-target interaction consists of a high amount of 
complementarity the result is mRNA degradation; whereas with a decreasing 
amount of complementarity the function as regulating mechanism of gene 
translational repression is increasing. It is important to clarify, that miRNAs are not 
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working in a ‘black’ or ‘white’ mode by turning their targets totally on or off; they are 
fine tuning gene expression113, 134. 
 
Figure 1-4:  MicroRNA processing in nucleus and cytoplasm (reproduced from 132) 
 
For microRNAs themselves, their appearance is also sometimes described to be on 
or off. But even if some miRNAs have very high temporal (e.g. let-7 in 
Caenorhabditis elegans development135) and local (e.g. miR-124 in the brain136) 




on different expression levels. The strict dichotomous model can be considered as 
exceptional cases136. 
The majority of miRNA effects are mediated by a decreased level of target mRNA, 
but also effects with an exclusive decrease of resulting protein expression are 
known, which can be caused by e.g. induced decapping or altered protein binding137. 
Bringing this observations in a practical context one can say that the observation of 
mRNA levels can be used to indicate miRNA targeting, but means also that the use 
of only mRNA profiling to determine miR targets may still miss relevant target genes, 
because the change of mRNA level might be small and not all targets show a 
decrease in expression129. 
An interesting fact about microRNAs is their ability of having opposing functions in 
different systems, which can illustrate the varying miRNA communications in 
different contexts. Given as an example, miR-125b can be downregulated in various 
cancers, such as hepatocellular, breast and lung. On the other hand, same miR-
125b is associated to be upregulated in colorectal, pancreatic and gastric cancers as 
well as in some leukemias138. These findings show an oncogenic but also a tumor 
suppressive function of miR-125b, very specific to the corresponding environment. 
This particular difference is explained by the targets of miR-125b, such is p53. In 
above mentioned cancer tissues, where miR-125b is overexpressed, the result is a 
loss of p53 which blocks apoptosis. In other cancer tissues, p53 has a higher 
potential to be mutated and the downregulation of miR-125b leads to an expression 
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of oncogenic targets, such is epidermal growth factor receptor (EGFR) family 
members ERRB2/3 in breast cancer138. 
Also, even if microRNAs have been associated with single pathogenic outcomes 
they have very differing appearance patterns between tissue and serum. For 
instance liver-specific miR-122, which has been associated with downregulation in 
liver tissue in NAFLD in multiple studies139, is showing a clear increase of 
appearance in corresponding individuals’ serum97. As this miRNA has also been in 
the focus of investigation of the experimental part of the work in hand, both this 
observations could be validated. This can be explained by the fact that damaged 
hepatocytes release the miRNA into the blood140-142, but gives an example about the 
complexity of interpreting the level of miRNA appearance. 
 
1.3.2 MiRNAs in metabolic syndrome and liver disease 
In the following, the key interacting miRNAs in relevant organs of the metabolic 
syndrome will be summarized, with more detailed information on their role in the 
context of NAFLD and rounded up with the emerging role of miRNAs in other 
pathogenic liver manifestations. 
1.3.2.1 MiRNAs in the pancreas 
The pancreatic islets consist of α- and β-cells. These play an important role in the 
context of metabolic body functions by producing and releasing insulin and 




other tissues. Changes in β-cells function and increased apoptosis can lead into a 
manifestation of T2DM. Recent studies showed the crucial interaction of miRNAs as 
mediators in the development of pancreatic β-cells but also in the induction of their 
dysfunction143. 
One of the first studies bringing miRNAs in the context of pancreatic β-cell 
development showed that the loss of the dicer protein lead to a reduction in β-cell 
mass as well as to an increase in development of hyperglycemia and T2DM144, 145. 
Further studies determined a crucial role for specific miRNAs in β-cell development, 
all started with miR-375, which showed a high increase in expression146. Also, the 
onset of hyperglycemia and impaired β-cell proliferation correlates with miR-375 
silencing147. 
Several miRNAs, including miR-199, miR-383, miR-34a, miR-146a, miR-187, miR-
15a, miR-30a, miR-30d, miR-96, miR-133, miR-148 and miR-182 have been shown 
to be involved in the progression of T2DM, pancreatic function, in the insulin 
synthesis regulation and secretion, and dysregulated levels of FFA and glucose143, 
148-157. 
An important and highly conserved miRNA family in this context is miR-33. These 
miRNAs, with their information provided in the intronic sections of the SREBP genes 
in organisms ranging from drosophila to humans158-161 show high impact on targets 
involved in the cholesterol export, such is e.g. the adenosine triphosphate binding 
cassette (ABC) transporters ABCA1 and ABCG1 and the endolysosomal transport 
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protein Niemann-Pick C1 (NPC1)161. Their crucial roles have been shown not only in 
the maintenance of cholesterol homeostasis, but also in regulation of fatty acid 
metabolism and insulin signaling162. MiR-33 has putative binding sites in the 3’ 
untranslated region (3’UTR) of carnitine O-octaniltransferase (CROT), carnitine 
palmitoyltransferase 1A (CPT1a), hydroxyacyl-CoA-dehydrogenase (HADHB), AMP 
kinase subunit-α (AMPKα), and insulin receptor substrate 2 (IRS2) and is involved in 
gene expression of these genes, which has the direct consequence of a reduction of 
insulin signaling and fatty acid oxidation162. In summary miR-33a and –b in 
interaction with SREBPs are main regulators in the cholesterol metabolism, insulin 
signaling and fatty acid oxidation, which are major risk factors involved in the 
development of T2DM and the metabolic syndrome162-165. 
1.3.2.2 MiRNAs in white adipose tissue 
The white adipose tissue (WAT) is the primary organ in the uptake and storage of 
excess circulating lipids. Therefore, WAT is a key player in the maintenance of 
metabolic function of the whole body and is involved in insulin sensitivity and 
appetite regulation by releasing signaling molecules, such as adiponectin and 
leptin166, 167. MetS associated obesity – characterized by increased accumulation of 
abdominal fat - is often involved in the development of hypertension, dyslipidemia 
and insulin resistance2, which means that either excessive lipid accumulation or 
genetic abnormalities in WAT can also lead to various manifestations of the 




The differentiation of pre-adipocytes into adipocytes, which are responsible for 
uptake and storage of circulating lipids and glucose, is mediated by a well 
investigated signaling cascade which involves the transcription factors PPARγ, 
SREBP-1 and C/EBPα/β (CCAAT/enhancer-binding protein alpha/beta). 
 
 Involved miRNAs 
Promotion of 
adipogenesis  
miRNA cluster miR-17-92, miR-21, miR-26b, miR-30, miR-103, miR-





let-7, miR-15a, miR-22, miR-27a/b, miR-130, miR-138, miR-155, 
mirR-193a/b, miR-205, miR-221, miR-222, miR-224, miR-344, miR-
365, miR-369-5p and miR-448186-201 
Table 1: MiRNAs involved in adipogenesis and adipocyte differentiation 
 
Several microRNAs have been described to be involved in WAT differentiation 
(Table 1); also several of these displayed miRNAs show a difference in expression 





1.3.2.3 MiRNAs in the liver 
MiRNAs have been proven to play a crucial role in liver metabolism, growth and 
regeneration as well as in disease. 
The fact that miRNAs are key mediators in lipid metabolism, insulin signaling, cell 
growth and differentiation, apoptosis as well as inflammation leads to the conclusion, 
that miRNAs are playing a crucial role in the pathogenesis of the manifestation of the 
metabolic syndrome in the liver – into NAFLD. 
An increasing number of studies are investigating different miRNA expression 
patterns related to the manifestation of NAFLD and the progression from bland 
steatosis to NASH. Among those, several already have been described and 
addressed above as key regulators of glucose-, cholesterol- and lipid-metabolism, 
which might lead to the conclusion, that hepatic deregulation of those miRNAs could 
cause intra-hepatic excessive accumulation of triglycerides and fatty acids202. 
The most abundant miRNA in the liver and also the first which could be correlated 
with lipid metabolism and homeostasis is miR-122203. The incidence of this miRNA is 
one of the main targets of the experimental part of this work. It has been investigated 
in liver tissue (see 4 Second manuscript) as well as in serum (see 3 First 
manuscript). In murine studies, miR-122 inhibition lead to a significant reduction of 
plasma cholesterol and increased levels of genes involved in hepatic cholesterol 
synthesis, e.g. 3-hydroxy-3-methylglutaryl-Coa synthase 1 (Hmgcs1), 3-hydroxy-3-




(Dhcr7)204. In another murine study, a group could show how silencing of miR-122, 
based on antisense-nucleotides (antagomirs), increases the fatty acid β-oxidation 
pathway and decreases fatty acid and cholesterol biosynthesis205. 
Different animal models of NASH could also show other miRNA expression patterns 
which could be associated with the manifestation of the disease. Hepatic miRNA 
expression in a rat model, fed with hypercaloric diet enriched in fat (HFD) and 
fructose (HFD-HFr) showed an increase of miR-200a, miR-200b and miR-429 
expression and a concomitant decrease in expression of miR-27a, miR-451 and 
again miR-122206. A C57BL/6J and DBA/2J mice model on a methyl-deficient diet, 
showed hepatic over-expression of miR-34a, miR-155, miR-200b and miR-221 
whereas miR-29c, miR-122, miR-203 and miR-192 were significantly down 
regulated207. The latter was also part of the experimental design of the work in hand 
and will be further addressed later in this chapter. MiR-15b also showed 
characteristics of a key regulator of lipid metabolism in an animal model: Two 
studies, based on a rat HFD model and on the L02 hepatocyte cell line treated with 
FFA (palmitate) in culture, could show that in both models miR-15b was highly 
overexpressed, glucose consumption was reduced and triglyceride levels were 
altered. By taking these findings together, one could assume an increased risk of 
NAFLD onset, triggered by augmented miR-15b expression, which leads to an 
altered glucose and lipid metabolism208. 
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A wide range of miRNAs where described in context with NAFLD pathogenesis. In 
an in vitro study, miR-10b lead to an increase of the triglyceride levels interacting 
with PPARα, which is involved in the catabolism of fatty acids209 (1.2.2.). Other 
candidate miRNAs important to mention in this context are miR-33a and miR-33b 
which have been already described as an important miRNA family in pancreatic 
context (1.3.2.1). Those are located intronic within SREBF2 and SREBF1 genes and 
have positive influence on the expression of lipogenic as well as cholesterogenic 
genes210. Numerous studies have described miR-33a/b in close functional 
interaction with hepatic lipogenesis and cholesterol homeostasis161, 162. The earlier 
addressed (1.3.2.1) involvement in regulation of post-transcriptional repression of 
ABCA1 renders it a key mediator in the binding process from cholesterol to 
apolipoprotein A1 (APOA1) during HDL formation211. Furthermore, Goedeke et al. 
could describe a regulatory function of miR-33 family in SREBP target genes by 
interacting with the deacetylase NAD+ dependent sirtuin 6 (SIRT6) which has also 
influence on lipid and glucose homeostasis212. 
MiRNAs are not only connected to fatty liver disease, as their influence could also be 
shown on other entities of liver pathology. In the context of hepatitis B virus (HBV)-
related liver disease, a panel of miRNAs - miR-602, miR-96, miR-29c and miR-148 - 
has been shown to be related to disease progression and virus infection213-216. 
These studies comprised detailed information about miRNA interactions in viral 
infections, including the fact that overexpression of miR-602 could be shown in the 




and HCC; its crucial role in hepatocarcinogenesis is manifested by regulation of 
tumor suppressive gene Ras association domain family 1 isoform A (RASSF1A)216. 
In diseases related to hepatitis C virus (HCV) infection, miR-155 is playing an 
important role by promoting tumorigenesis and hepatocyte proliferation. The 
mechanism is based on Wnt signaling activation and therefore miR-155 has been 
suggested as useful biomarker for HCV related HCC217. 
This miR-155 has also been shown and described to be involved in innate and 
adaptive immune responses in the context of liver inflammation218. Liver 
inflammation in general can be caused by various contributing factors. Recently, 
miRNAs have been suggested to play a fine tuning role, triggering the intensity of 
the inflammatory response by interaction with central signaling molecules of liver 
inflammation. In this context eight miRNAs have been highlighted: miR-125b, miR-
146a, miR-150, miR-181, let-7, miR-21, miR-155 and miR-132219, 220.  
It has been shown in the past that alcoholic steatohepatitis also leads to 
dysregulation of miRNA expression in the liver. A prominent example would be 
increased expression of miR-132221, which has been shown to be a key player in 
inflammation in the past219, 220, 222. Alcohol consumption also leads to an elevated 
miR-212 level in the gut, which causes an inhibition of ZO-1 protein level, a tight 
junction protein, and is involved in alcohol-induced gut permeability223. In addition, 
miR-217 has been shown to be a key player in alcohol-induced steatosis since this 
miRNA is regulating SIRT1, an essential regulatory metabolic transcription factor224. 
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It has been discussed under 1.2.4 that a crucial point in NAFLD diagnosis is the 
determination of alcohol consumption habits. Defining a miRNA expression pattern 
to discriminate AFLD from NAFLD patients would represent another important aim to 
shed new light in this difficult clinical differentiation. 
These implementations at least give a hint towards the important role of microRNAs 
in the context of the metabolic syndrome and in the liver. The given examples should 
be a sufficient survey for the manifold facets of miRNA regulation in hepatic health 
and disease. 
1.3.3 MiRNAs in circulating blood of NAFLD patients 
MiRNAs have been shown to bear diagnostic and prognostic potential as markers in 
various cancer forms, such as breast-, ovarian-, lung-, prostate- and liver-cancer. 
Also, many other non-tumoral pathologies have been shown to be associated with 
miRNA expression in serum. Not even ten years ago, scientists proofed the 
presence of miRNAs is not intracellular- specific, as they could be detected in 
plasma, platelets, erythrocytes, and nucleated blood cells225-227. In blood plasma an 
enormous stability, resistant against numerous influences, could be shown225, 227. 
The following intensive search for the ‘protective factor’ avoiding their degradation 
brought interesting findings: the immense stability was caused by the fact, that 
miRNAs circulating in plasma and serum can be packaged in microparticles such as 
apoptotic bodies, exosomes or microvesicles228, 229. Another option to prevent their 
degradation is the association with RNA binding proteins, such as Argonaute2 




circulating microparticles suggested them to be involved in cell-cell-communication. 
This interesting field of investigation is gaining more and more importance; hence 
first results already have given a glance about the role of miRNAs in cell-cell 
interaction228, 232. First proven interactions of miRNAs to be involved in the 
pathophysiological progression of NAFLD in the liver have led into related studies in 
this field. Serum levels of miRNAs have been evaluated with the aim of describing 
potential non-invasive biomarkers for monitoring and diagnosis of NAFLD233. 
 
1.3.3.1 MiR-122, miR-21 and miR-192 
The three miRNAs miR-122, -21 and -192 are of special interest within the 
experimental part this thesis (see 3 First manuscript). In the following part, their 
relevance will be discussed in various aspects. 
In a study conducted by Yamada et al., miRNAs were evaluated in a Japanese study 
cohort with hepatic steatosis (diagnosed by ultrasound). The results showed 
increased levels of four miRNAs, all known to be implicated in cholesterol and fatty 
acid homeostasis. The different levels of miR-34a, miR-21, miR-451 and miR-122 
showed differential expression comparing NAFLD patients and healthy controls234. 
These finding confirmed previous related studies, showing a correlation between 
altered miRNA expression and the pathogenesis of NAFLD. MiR-122 and -34a were 
shown before to have a significantly increased expression in serum of NASH 
patients, also positively correlated with their stage of inflammation and fibrosis235. 
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Miyaaki et al. could demonstrate an altered level of miR-122 in patients’ sera, 
correlating with progression of NAFLD and fibrotic liver damage236. The correlation 
could be explained by the fact, that persistent liver damage is causing a leakage 
from hepatocytes, which are the main source of miR-122. Damaged hepatocytes are 
releasing the miRNA into circulating blood leading to altered mir-122 levels235. 
Interestingly, Li et al. described the functional linkage between fibrotic liver damage 
and miR-122 which is mediated by an inhibitory effect on the stellate cell activation 
and collagen deposition within the liver237. 
A very recent study showed also an increased elevation of three miRNAs in NAFLD 
patients’ serum; again miR-122, but also miR-192 and miR-37597. The findings 
presented in this particular study had also influence on the experimental design of 
the present study. One major strength of this study is the fact that the NAFLD 
diagnosis was based on liver biopsy, enabling a definite differentiation between 
bland steatosis and steatohepatitis. For the first time, a differential regulation of the 
three miRNA has been observed during the course of the disease from NAFL to 
NASH. The evaluation of their data detected for miR-122 a higher potential for 
NASH prediction compared to classic biomarkers as ALT, AST and CK-18 fragment 
levels. From these data and the fact, that miR-122 is highly expressed in the liver 
and shows a high rate of detection in serum, one can suggest that miR-122 has a 
high potential as non-invasive biomarker for NAFLD progression and fibrosis 




Before Pirola et al. presented their results mentioned above97; miR-192 has not been 
brought in context with NAFLD detection. The miRNA is known to be upregulated by 
the pro-fibrotic cytokine TGFβ1238. It also has been shown to share a pri-miRNA with 
miR-194. Besides the liver, miR-192 plays a crucial role in the kidney and in diabetic 
nephropathy238. This might uncover the bridge between different pathologies within 
the metabolic syndrome. MIR-192/-194 are both described to have a high 
expression in specific tissue including the liver239. 
One of the new findings that could be shown by the results of the study at hand is 
the differential expression level of miR-21 in patients’ serum comparing NASH 
patients with NAFL patients and healthy controls (see chapter 3). An upregulation in 
NAFLD patients’ sera has been shown before, but without discrimination between 
NAFL and NASH234. A possible reason could be that a classification of patients was 
mostly based on liver ultrasound only as discussed above.  
As miR-21 was shown to be connected to more than one disease, interdisciplinary 
research to clarify its occurrence and function was undertaken and is still ongoing. A 
critical meta-analysis by Haider et al. is concerning miR-21 as biomarker in context 
of cardiac diseases and viral hepatitis240. Five studies showed an increase of miR-21 
in context of cardiovascular disease240. In liver disease, respective miRNA has 
shown potential as a diagnostic biomarker for hepatitis B241 and C242 virus. Going 
one step further in those particular studies, miR-21 was also brought into the context 
of HCC in connection with viral hepatitis243. 
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In the context of steatosis, the functional role of miR-21 was first explained via 
lycopene, an unsaturated carotenoid antioxidant, which can decrease hepatic 
steatosis by suppression of its downstream target fatty acid-binding protein 7 
(FABP7) in mice244. As miR-21 was also one of the first oncomirs, a lot of its targets 
are known and described as tumour suppressor genes. Prominent examples would 
be acidic (leucine-rich) nuclear phosphoprotein 32 family, member A (ANP32A), 
phosphatase and tensin homolog (PTEN) and SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, subfamily A member 4245, 246. 
An upregulation of miR-21 could be detected in hepatocytes after unsaturated fatty 
acid treatment, mediated by NF-κBp65/ mammalian target of rapamycin (mTOR)-
complex. The determined mechanism was a specific 3’- UTR binding of miR-21 to 
the PTEN messenger transcript, initiating its degradation. With this important study 
the gap could be closed, explaining decreased PTEN expression in HFD treated rats 
but also in NAFLD patients, suffering from obesity247. 
The considerations of this knowledge about the multiple functions of the miRNA can 
be taken as an argument to use miR-21 in combination with other biomarkers has an 
even higher potential than using it exclusively. 
1.3.3.2 Other miRNAs 
As it has been mentioned in the previous section already, not only circulating miR-
122, -192 and -21 have been set into context with NAFLD. Looking for a possible 




34a regulative interaction with pro-apoptotic genes and tumor suppressor p53 
transcription in NAFLD progression248. The elevated levels of miR-37597 are in line 
with its role as key mediator of glucose homeostasis. Also, it is an essential part in 
adaptive β-cell expansion which is known to be one response to increasing insulin 
demand in insulin resistance147. 
The analysis of miRNA levels in serum leaves room for a wide spectrum of plausible 
studies for interconnections. Following this approach, a cohort study with NAFLD 
patients could show a correlated increase of blood glucose levels, BMI or ALT levels 
parallel with miR-15b serum level. These findings could also suggest miR-15b for a 
potential marker as potential diagnostic candidate for NAFLD210, but could not bring 
more satisfying results until today. 
The presented data is showing the high potential of miRNAs in circulation and their 
use as potential diagnostic biomarkers. The knowledge newly generated in this 
particular area will be addressed in detail in the manuscript shown in chapter 3. 
 
1.3.4 MiRNAs in NAFLD liver tissue 
The foregoing chapter has concerned the role of miRNAs in the context of NAFLD in 
circulating blood. In 1.2.2 it has been stated that the pathophysiology of NAFLD is 
not fully understood. Even if numerous studies have been undertaken within that 
area, several aspects of regulation and progression of the disease remain unclear. 
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First presented results have shown the potential role of miRNAs as key mediators in 
fatty liver disease139, 235, but the full context of their interactions is still in the focus of 
scientific investigation. An exploratory approach investigating the differences of 
miRNA expression in NAFL and NASH patients and healthy controls will be 
discussed in 4, Second manuscript within this thesis. This part of the experimental 
set-up was dedicated to explore miRNAs impacting the progression from simple 
steatosis to liver inflammation but also the initial manifestation of NAFLD. Evaluating 
the results, four miRNAs became targets of further investigations – miR-122, -21, -
223 and -638. The following part is considering relevant knowledge about these 
candidates. 
1.3.4.1 MiR-122, miR-21, miR-223 and miR-638 
The role of miRNA 122 has been in the focus of this disquisition before. As the most 
abundant miRNA within the liver, it was also the first with a confirmed correlation to 
homeostasis and lipid metabolism203. The groundwork for this knowledge was laid by 
a study by Cheung et al.; their work showed a highly significant downregulation of 
miR-122 in NASH patients. The effects on its targets were functionally assessed by 
overexpression and silencing in an in vitro study. Several effects could be shown in 
the field of protein translation, cell proliferation, inflammation, apoptosis, oxidative 
stress and metabolism. The overexpression led to a downregulation of miR-122 
targets whereas an antagomir based silencing caused a significantly increased 
protein level. These results suggested that lower levels of miR-122 stand in a direct 




pathogenesis of NASH139. With this knowledge, several other studies could proof a 
relationship between the miR-122 and NAFLD. However, this miR is still in the focus 
of investigation as some targets and their regulating functions remain unexplored. 
Some known facts about miR-21 have been already addressed in chapter 1.3.3.1 – 
it has an oncomir function and one of its known targets is PTEN. Still, the direct 
functional connection of miR-21 and hepatic steatosis remains unclear. As an 
upregulation of the miRNA in hepatic tissue could be shown247 and could also be 
validated in the experimental setup of this work (see chapter 4), first approaches to 
circumvent this effect have been investigated. For example Seeger et al. recently 
published a study were they pharmacologically inhibited miR-21 on long-term in a 
rodent model of metabolic syndrome and obesity. The result was a significant 
reduction of body weight, serum triglycerides and adipocyte size249. Direct 
correlations to TGFβ-receptor 2 (TGFBR2)249 as well as its demonstrated role in 
regulation of PPARɑ in the context of beta-oxidation250 show the enormous potential 
of miR-21 as a key mediator of MetS and NAFLD and suggest it to remain in the 
focus of scientific investigation. 
MiR-223 is a rather unexplored candidate in the context of human NAFLD. However, 
an altered hepatic expression in a rodent model of fatty liver disease could be 
observed251, a fact that could also be validated in human liver tissue in the 
experimental part of this study (see chapter 4). The mouse model showed 
deregulation of hepatic iron homeostasis251. An in vitro study suggested recently that 
 
46 
miR-223 is involved in selective HDL cholesterol uptake by inhibition of hepatic 
scavenger receptor class B type I (SR-BI). This implies an important role of miRNAs 
in the modulation of cholesterol metabolism252. However, the full influence on 
NAFLD development and progression could not be clarified, yet. MiR-223 has also 
been investigated in the context of HCC where its contribution to the regulation of 
cell proliferation is suggested as it has been described in the context of colorectal 
cancer253. 
MiRNA 638 has not been brought into the context of metabolic manifestations before 
at all. Even in the extended context of liver diseases, there was no relevant data 
existing, until very recently Kumar et al. showed an antiviral potential of the miRNA 
in the context of HBV infections254. Other studies showed different regulations in 
colorectal cancer patients255, 256 but are lacking a clarification of its functional 
pathways. A verification of predicted target genes, suggesting a regulatory role in the 
context of metabolic manifestations or a potential contribution to NAFLD 
development represent one of the desired goals addressed in this work. 
 
1.4 Genes involved in NAFLD 
In the experimental setup of the work in hand, not only the different expression 
patterns of miRNAs are in the focus of investigation, but also the expression of 
mRNAs in NAFLD patients and cultures cell lines is addressed. The aim of this part 




potential targets. This functional evaluation should bring new light in 
pathophysiological aspects of miRNAs in the context of NAFLD and should be the 
groundwork for subsequent functional analysis in an in vitro assay in cell culture. 
The obtained results will be discussed in detail under 4, Second manuscript. In this 
context, three genes are in the focus of further investigations. In chapter 1.2.2, 
several genes, pathways and receptors standing in relation to the progression of 
NAFLD have been addressed. A detailed introduction of all relevant genes would go 
beyond the scope of this work; this is why the three prementioned genes of interest 
were selected for a more detailed treatise. 
 
1.4.1 FASN and JUN 
The gene of fatty acid synthase (FASN) is a potential target of three miRNAs in the 
focus of interest within this work – miR-122, -223 and -21. 
FASN is often mentioned in the context of lipid homeostasis, a complex molecular 
mechanism, regulated by several receptors which are also known in the context of 
NAFLD, for instance LXR257 and PXR258, 259. Fatty acid synthase (FAS) in one of the 
major lipogenic enzymes; and - as the liver is the main organ for lipogenesis - the 
expression level is constitutively high. Being regulated by SREBP1c210 and directly 
associated with insulin resistance induced hepatic steatosis260, FAS is suggested to 
be one of the targets of differentially expressed miR-122, -223 and -21 in NAFLD 
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patients. A possible alteration between the mRNA levels in NASH patients compared 
to NAFL patients would also be plausible, as the level of insulin resistance is also 
rising within this progression. 
The proto-oncogene JUN is encoding for the C-Jun protein. C-Jun is subject of 
regulation by extracellular stimuli, such as oxidative stress and pro-inflammatory 
cytokines; factors which have also been associated with hepatic inflammation261. 
The JUN N-terminal kinases (JNKs) –pathway is relevant for JUN activation in cell 
proliferation and stress induced apoptosis262. In hepatocytes, C-Jun has been 
demonstrated to bear protective function from apoptosis, also suggesting the protein 
to have a protective function against apoptosis in HCC263. 
JUN transcripts are targets of the miRNA candidates of interest miR-21 and -223. 
The consideration of the gene as a relevant factor is based on the fact, that the JNK 
pathway is relevant for IRS-1/2 phosphorylation leading to insulin resistance264, 265 
and SREBP-1a phosphorylation266. The latter was a crucial factor in terms of obesity 
phenotype and fatty liver development in a rodent study. The transgenic animals 




The gene perilipin5 (PLIN5) is a member of the Perilipin family and is encoding for 




essential for coating intracellular lipid storage droplets as well as their protection 
from lipolytic degradation267. The prevention from lipolysis is a crucial step in the 
development of hepatocellular steatosis. The expression of perilipins is highly 
abundant to adipocyte and steroidogenic cells, as for instance hepatocytes268-270. 
The function of perilipin is well investigated. The perilipin knockout in a mouse model 
showed a decrease in adipose tissue mass which was highly significant271, 272. The 
ability of the cells to respond to lipolytic stimuli disappeared and a continuously high 
level of lipolysis could be detected. Lipolysis is controlled by the phosphorylation 
state of perilipin272-277. A correlation in expression between perilipins and PPARs 
could be detected suggesting a regulative function267. All these facts already 
predispose PLIN5 as a gene of interest in NAFLD development. Another reason 
would be the fact that it is one of the few predicted targets of selected miRNA of 
interest 638. 
Following this, the potential interaction between PLIN5, miR-638 and the 
development of NAFLD was investigated in one part of the experimental setting of 









2.1 Aim of the project and addressed topics 
NAFLD with its two different manifestations NAFL and NASH is an increasing health 
problem in western countries. Whereas patients suffering from simple steatosis have 
no influence on mortality, NASH patients have an increased risk to develop severe 
liver disease, such as fibrosis, cirrhosis and HCC. The pathophysiology of the 
development of NAFLD is still not entirely clear, as well is the search for stimuli, 
triggering or regulating the progression from NAFL to NASH still ongoing. 
Considering the diagnosis of NAFLD, the gold standard to differentiate between 
NAFL and NASH is still liver biopsy with histological examination, as no valid 
biomarker has been described yet. Within this work, these two fields of interest were 
considered. On the one hand, miRNAs expression in NAFLD patients’ serum and 
healthy controls was detected and evaluated, aiming to define an expression pattern 
valid as a NASH biomarker. On the other hand, miRNA expression patterns were 
investigated in tissue obtained from human liver biopsies. The aim was to find 
differentially expressed miRNAs responsible for the manifestation or the progression 
of the disease. Potential candidates were further addressed in functional studies in 






Within this work the following topics were addressed: 
• Evaluation of miRNA expression patterns in serum as well as design of a 
simplified scoring system in combination with the apoptosis marker CK-18 
fragment level to evaluate its prognostic potential as NASH biomarker. 
• Contribution of four miRNAs in human liver tissue to the development and 
progression of NAFLD, followed by functional studies to evaluate the 
pathophysiological mechanisms.  
When this project was started some relevant miRNAs in the context of NAFLD were 
already defined, however, data from human liver tissue were lacking or a clear 
differentiation between NAFL and NASH was not obtained. During the time of this 
work more and more evidence arose that miRNAs play a crucial role as well in 
NAFLD pathophysiology as also in the context of NAFLD diagnosis. It could also be 
shown that data from serum and liver tissue are rarely subject of comparable 
expression. We could confirm earlier results obtained by other groups with our data. 
Our study was aiming to identify functionally relevant miRNAs in liver tissue as 
mediators of central signaling pathways and clinically relevant pathophysiological 
events in fatty liver disease. The data obtained in the serum study were used for the 
detection of the role of certain miRNAs as potential prognostic biomarkers to monitor 





2.2 Contribution to further projects during the time of the 
dissertation  
(Not addressed in detail within this work) 
Impact of genetic SLC28 transporter and ITPA variants on ribavirin 
serum level, hemoglobin drop and therapeutic response in patients 
with HCV infection 
Various independent studies discuss a potential impact of genetic SLC28 transporter 
and inosinetriphosphatase (ITPA) variants on the serum level of ribavirin, the 
hemoglobin drop and the influence on the therapeutic outcome in patients suffering 
from a hepatitis C virus (HCV) infection. A cohort study assessed SNP – 
associations with their impact on HCV treatment. 
Publication 
Rau M, Stickel F, Russmann S, Manser CN, Becker PP, Weisskopf M, Schmitt J, 
Dill MT, Dufour JF, Moradpour D, Semela D, Müllhaupt B, Geier A; Swiss Hepatitis 
C Cohort Study Group (SCCS). (2013) Impact of genetic SLC28 transporter and 
ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in 
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Liver biopsies are the current gold standard in non-alcoholic steatohepatitis (NASH) diagno-
sis. Their invasive nature, however, still carries an increased risk for patients’ health. The
development of non-invasive diagnostic tools to differentiate between bland steatosis
(NAFL) and NASH remains crucial. The aim of this study is the evaluation of investigated
circulating microRNAs in combination with new targets in order to optimize the discrimina-
tion of NASH patients by non-invasive serum biomarkers.
Methods
Serum profiles of four microRNAs were evaluated in two cohorts consisting of 137 NAFLD
patients and 61 healthy controls. In a binary logistic regression model microRNAs of rele-
vance were detected. Correlation of microRNA appearance with known biomarkers like
ALT and CK18-Asp396 was evaluated. A simplified scoring model was developed, combin-
ing the levels of microRNA in circulation and CK18-Asp396 fragments. Receiver operating
characteristics were used to evaluate the potential of discriminating NASH.
Results
The new finding of our study is the different profile of circulating miR-21 in NASH patients
(p<0.0001). Also, it validates recently published results of miR-122 and miR-192 to be differ-
entially regulated in NAFL and NASH. Combined microRNA expression profiles with CK18-
Asp396 fragment level scoring model had a higher potential of NASH prediction compared
to other risk biomarkers (AUROC = 0.83, 95% CI = 0.754–0.908; p<0.001). Evaluation of
score model for NAFL (Score = 0) and NASH (Score = 4) had shown high rates of sensitivity
(91%) and specificity (83%).
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Conclusions
Our study defines candidates for a combined model of miRNAs and CK18-Asp396 levels
relevant as a promising expansion for diagnosis and in turn treatment of NASH.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in devel-
oped countries with a prevalence of 20 to 35% [1, 2]. Non-alcoholic fatty liver (NAFL) is
defined as bland steatosis and must be distinguished from non-alcoholic steatohepatitis
(NASH) which is characterized by inflammatory infiltrates, ballooning and necroapoptosis. 5%
to 20% of NAFLD patients develop a progression from NAFL to NASH. This is of particular
importance since the presence of NASH and/or advanced fibrosis has been associated with an
increased overall mortality in these patients [3, 4]. Liver biopsy with subsequent histological
examination still remains the gold standard in clinical practice to distinguish NAFL from
NASH. A common scoring system to differentiate between NAFL and NASH is the NAFLD
activity score (NAS) which is defined by the sum score of steatosis, ballooning, and lobular
inflammation [5].
For optimal follow-up and treatment of NAFLD patients, development of non-invasive
diagnostic tools to differentiate between NAFL and NASH remains crucial. In clinical practice,
clinical presentation including age, BMI, presence of type 2 diabetes and routine parameters
such as AST and ALT predict liver-related events [6–8]. Based on these observations the
NAFLD risk score has been developed [9]. Cytokeratin-18 (CK18-Asp396), an intermediary fil-
ament protein proteolytically cleaved by caspases during liver cell apoptosis [10, 11]. The resul-
tant CK18-Asp396 fragments have been investigated as a liver specific apoptosis and NASH
biomarker [12]. However, the sensitivity and positive predictive value for NASH is low [13]
and current practice guideline do not recommended CK18-Asp396 fragments as a single
marker for the detection of NASH [14]. Reliable serum biomarkers are still not available and
further promising candidates such as the interleukin 1 receptor antagonist (IL-1RA) have been
investigated in NASH patients [15].
Since microRNAs (miRNAs) have been discovered, scientists demonstrated a regulative
function in various gene expression pathways. MiRNAs are very stable in clinical samples as
they are resistant to the degradation by ribonucleases. This is one reason why circulating miR-
NAs have been proposed as attractive diagnostic tools for non-invasive assessment of a patho-
logical state of their origin organ/ tissue from peripheral blood [16]. The range of miRNA
applications is getting broader as they are used in different clinical settings for early disease
detection and monitoring of disease progression [17]. Very recently, Pirola et al. made an
attractive approach to improve the non-invasive assessment of NAFLD by using miRNAs as
potential diagnostic NASH markers [17].
Given the vast variability of miRNA results in different studies assessing the same disease
entity and important methodological differences between these studies [18–21], validation of
these results together with the evaluation of additional miRNA candidates is warranted. We
hypothesize that miRNAs in circulation as molecular marker of cell damage would indicate the
presence of NASH and contribute in combination to routine serum markers. The aim of this
study is to establish potential diagnostic miRNAs as biomarkers for the differentiation between
NAFL and NASH by defining a specific single or a grouped expression pattern for non-invasive
NASH diagnosis.
Performance of microRNAs as Combination Biomarker in NASH-Patients
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Material and Methods
Study design, patients and healthy controls
A total of 137 NAFLD patients>18 years and 61 healthy controls (HC) were enrolled between
July 2007 and August 2014. NAFLD patients consisted of two different cohorts of patients, one
with a majority of moderate obesity from Hannover Medical School (MOC; n = 81; 16 NAFL/
65 NASH) and one with a majority of severely obese patients mostly undergoing bariatric sur-
gery fromWürzburg University Hospital (SOC; n = 56; 34 NAFL/ 22 NASH). Blood samples
were collected prior to any therapeutic procedure. Table 1 shows baseline parameters of the
Table 1. Baseline patient characteristics of study cohorts.
‘Severely obese cohort‘ (SOC)
Total: N = 99 (%) HC: N = 43 (43%) NAFL: N = 34 (34%) NASH: N = 22 (23%)
Sex, N (%): Male; Female 11 (26%); 32 (74%) 8 (24%); 26 (76%) 7 (32%); 15 (68%)
Age: Mean ± sd; Median (quartiles) 26.5 ± 3.2; 26 (21–37) 45.4 ± 10.6; 44.5 (22–64) 50.9 ± 10.8; 53 (30–77)
BMI: Mean ± sd; Median (quartiles) 21.4 ± 2.5; 21 (17.5–26.3) 49.4 ± 7.2; 49.7 (37.6–69.8) 48.7 ± 9.3; 47 (37–66.2)
Fasting glucose [mg/dl]:
Mean ± sd; Median (quartiles) n.d. 102 ± 24.5; 97 (71–178) 117.5 ± 51.5; 93.5 (71–244)
Triglycerides [mg/dl]: Mean ± sd; Median (quartiles) n.d. 166.7 ± 98.1; 143 (47–531) 188.2 ± 74.9; 162 (90–369)
Cholesterol total [mg/dl]: Mean ± sd; Median
(quartiles)
n.d. 197.7 ± 47.3;195 (114–307) 195.2 ± 28.7; 195 (128–258)
AST [U/l]: Mean ± sd; Median (quartiles) 20.4 ± 6.1; 19 (11.6–41.4) 30.8 ± 15.5; 25.5 (13.2–85.9) 45.9 ± 26.7; 36.3 (14–119
ALT [U/l]: Mean ± sd; Median (quartiles) 18.7 ± 8.0; 15.8 (10–46.6) 32.8 ± 18.2; 27 (13–179.4) 50.6 ± 20.3; 53.4 (19–89)
CK18-Asp396 [U/l]: Mean ± sd; Median (quartiles) 170.6 ± 54.8; 168 (91–
291)
235.8 ± 118.2; 218 (111–
646)
448.1 ± 252.4; 345 (139–996)
NAS: N = n.d./0/1-2/3/4; (%) 43/0/0/0/0; (100/0/0/0/0) 4/1/12/11/6; (12/3/35/32/18) 1/0/0/0/21; (5/0/0/0/95)
Fibroscan Elasticity [kPa]: Mean ± sd; Median
(quartiles)
4.3 ± 1.1; 4.1 (2.5–7.1) 9.3 ± 5.3; 8.1 (3.5–25.4) 13.1 ± 10.5; 10.4 (3.6–47.2)





‘Moderate obese cohort‘ (MOC)
Total: N = 99 (%) HC: N = 18 (18%) NAFL: N = 16 (16%) NASH: N = 65 (66%)
Sex, N (%): Male; Female 6 (33%); 12 (67%) 12 (75%); 4 (25%) 39 (60%); 26 (40%)
Age: Mean ± sd; Median (quartiles) 33.4 ± 9.3; 31 (24–57) 45.3 ± 10.5; 46 (21–63) 47.2 ± 11.7; 48 (19–71)
BMI: Mean ± sd; Median (quartiles) n.d. 31.6 ± 6.3; 31 (25–48.1) 30.6 ± 4.1; 30 (25.2–45.9)
Fasting glucose [mmol/l]: Mean ± sd; Median
(quartiles)
n.d. 6.2 ± 1.8; 6 (4.6–10.7) 6.1 ± 1.5; 6 (3.9–9.6)
Triglycerides [mg/dl]: Mean ± sd; Median (quartiles) n.d. 157.2 ± 112.0; 108 (61–502) 189.9 ± 124.9; 151 (64–736)
Cholesterol total [mmol/l]: Mean ± sd; Median
(quartiles)
n.d. 209 ± 30.4; 206 (143–259) 222.1 ± 56.4; 213 (143–403)
AST [U/l]: Mean ± sd; Median (quartiles) n.d. 43.8 ± 19.0; 38 (23–96) 49.7 ± 20.7; 44 (16–116)
ALT [U/l]: Mean ± sd; Median (quartiles) n.d. 66.9 ± 43.5; 60 (26–176) 82.2 ± 47.0; 73 (13–221)
CK18-Asp396 [U/l]: Mean ± sd; Median (quartiles) 125.2 ± 25.3; 124 (85–
185)
183.8 ± 86.8; 149 (79–429) 380.7 ± 318.1; 260 (78–1897)
NAS: N = n.d./0/1-2/3/4; (%) 18/0/0/0/0; (100/0/0/0/0)) 0/0/16/0/0; (0/0/100/0/0) 0/0/0/17/48; (0/0/0/26/74)
Fibroscan Elasticity [kPa]: Mean ± sd; Median
(quartiles)
n.d. 5.7 ± 1.4; 5 (3.3–9.1) 8.2 ± 4.5; 7 (3.7–25.7)
Fibrosis: N = n.d./0/1/2/3/4; (%) 18/0/0/0/0/0; (100/0/0/0/0/
0)
2/8/6/0/0/0; (12/50/38/0/0/0) 3/21/26/10/4/1; (5/32/40/15/6/
2))
Results are expressed as mean ± standard deviation, as well as median (quartiles) unless indicated differently.
doi:10.1371/journal.pone.0142661.t001
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moderate obese and severely obese cohort as well as controls. Patients with significant alcohol
consumption (females> 20g/day and males> 30g/day) and any pre-existing liver disease were
excluded. Healthy control subjects seeking a routine health check-up at the Würzburg Univer-
sity Hospital or Hannover Medical School had no evidence or history of liver pathology, unre-
markable liver ultrasound, normal liver stiffness and no elevation of serum transaminases AST
and ALT. Furthermore, history of coronary heart disease, hypertension, valvular disease, any
arrhythmia or systemic disease resulted in exclusion of controls from the study.
Routine clinical and laboratory parameters were determined at baseline (age, BMI, fasting
glucose, triglyceride, total cholesterol, AST, ALT, CK18-Asp396) and liver stiffness was mea-
sured by transient elastography (Fibroscan1). For all patients, liver biopsies have been
obtained either percutaneously or during bariatric surgery (frustule size>20 mm; min.10 por-
tal tracts); histology has been evaluated by an experienced pathologist, who was blinded to the
results of Fibroscan and defined the presence of NASH and the NAS score [5]. The study was
approved by the Ethics Committee of Hannover Medical School, the Ethics Committee of
Würzburg University, and the Zürich Cantonal Ethics Committee. Written informed consent
was obtained from each participant and the entire study was conducted in accordance with the
declaration of Helsinki.
CK18-Asp396 measurement
The apoptosis-associated neoepitope CK18-Asp396 was measured by using the M30-Apopto-
sense ELISA according to the manufacturer's instructions (Peviva, Bromma, Sweden) and as
described previously [22].
Blood samples and RNA isolation
Small RNA fraction was extracted from 200 μL serum using the miRCURY TM RNA isolation
kit—Biofluids (Exiqon A/S, Denmark) according to the manufacturer's protocol (v1.4; April
2014) with three minor variations. Specifically, before starting with isolation, 1μg of MS2 RNA
from bacteriophage MS2 (Roche, Switzerland) was added to stabilize RNA during cDNA syn-
thesis. Additional, 20 mg glycogen, RNA grade (Thermo Scientific) was added to inert co-pre-
cipitant of nucleic acids. The Exiqon UniSP6 Spike-in-Kit was added to monitor the yield of
RNA isolation via quantitative real-time PCR (RT-q-PCR). RNA was eluted from spin columns
in 50 μL nuclease-free water.
cDNA-synthesis and RT-q-PCR
RNA (2 μL) was reverse transcribed in 20 μL reactions using the miRCURY LNA Universal-
RT miRNA PCR kit (Exiqon A/S). The cDNA was diluted 1:40 and amplified in 10 μL PCR
reactions using specific LNA primer sets and the ExiLENT SYBR Green Master Mix (Exiqon-
A/S). The amplification was carried out on a 7900HT real-time PCR instrument (Applied Bio-
systems). As control, RT-q-PCR for miR-425 [23, 24] and miR-103 [25–27] (as reference miR-
NAs/ global mean [28–30]), miR-16 (as a reference to avoid the bias of relevant hemolysis) [31,
32] and UniSp6 (as monitor of efficiency of reverse transcription as recommended by provid-
ing company Exiqon for cDNA transcription [28]) were performed to guarantee equal quality
standard.
Statistics
Statistical analyses were performed with SPSS (Version 22, IBM, NY) and graphs were created
with Prism5 (GraphPad Software, La Jolla, CA).
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P-values< 0.05 were considered statistically significant (< 0.05, < 0.01, < 0.001,

< 0.0001). Quantitative data were expressed as mean ± standard deviation unless otherwise
indicated. For relative miRNA expression average expression of miR-103 and miR-425 was
considered for normalization; 2-Δ Ct–method was used. To compare miRNA expression,
Mann-Whitney U test was applied. For binary logistic regression with SPSS in combined group
(SOC and MOC) the origin of the sample was included as co-variable to correct for differences
between the subgroups. Correlation between variables was calculated using Spearman’s Rank
correlation test. Scoring of miRNA expression was performed by separating their expression in
the entire NAFLD group by median (S1 Table), giving a ‘0’ for lower and equal values (lower
risk) and a ‘1’ for higher values (higher risk), which was chosen to avoid bias regarding differ-
ent RNA concentrations. Sum scores were in a range between 0 and 3 (or 0 and 4 when includ-
ing CK18-Asp396 as a fourth parameter).
For characteristic factors in combined patient group (SOC and MOC), receiver operating
characteristic (ROC) curve was calculated and area under ROC (AUROC) was evaluated with
SPSS.
Correction for multiple testing was not applied, as the focus of the study was rather explor-
atory for the use of miRNAs as diagnostic biomarkers.
Results
Differential expression of circulating miRNAs
Four different miRNAs (miR-122, miR-192, miR-21, miR-223) which have been involved in
chronic inflammatory liver disease and particularly NAFLD [17, 19, 33, 34] were quantified in
patient sera. The evaluation of miR-122 in both cohorts showed significant expression profile
change between control group and simple steatosis group (p<0.0001) and a significant further
increase between NAFL and NASH (p<0.0001) (Fig 1). The difference between HC and NAFL
was significant in both cohorts (moderately obese (MOC) and severely obese (SOC) patients),
whereas the difference between NAFL and NASH was only significant in SOC (p = 0.0051). In
MOC, in spite of consistent direction of effects, statistical significance was not obtained (S1
and S2 Figs). For miR-192 the same pattern of detected miRNAs as for miR-122 has been
observed with a significant increase in NAFL and NASH compared to HC (Fig 1). Again, the
difference between NAFL and NASH was only significant in SOC (p = 0.0022) (S1 and S2
Figs). Although the absolute difference was small, a significant increase of miR-21 expression
was observed for the NASH group compared to both other groups (p<0.0001) and could be
detected for both cohorts in separate (Fig 1, S1 and S2 Figs) (p(SOC) = 0.0007; p(MOC) =
0.0075). No relevant change in miR-21 profile between controls and simple steatosis could be
observed in both cohorts. An increase of miR-223 expression profile in serum of NASH
patients compared to NAFL and HC was only detectable in the severely obese cohort
(p = 0.0338), but was absent in MOC (Fig 1, S1 and S2 Figs).
To compare miRNA profile level with histological scores, delta Ct measures were correlated
to the corresponding NAS. For three miRNAs 122, 192 and 21 a significant discrimination for
groups with NAS n.d. + 0–2, 3+4 and 5+ has been detected with an overall trend towards lower
delta Ct measures with increasing NAS (Fig 2).
Contribution of miRNA and baseline patient parameters to the presence
of NASH
In the following the statistical contribution of miRNA serum levels to the diagnosis of NASH
was investigated in relation to established baseline factors by applying binary logistic
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regression. Established predictive parameters such as age, sex and BMI were considered as can-
didate co-variables for adjustment if a significant difference between the groups was calculated.
However, none of those baseline parameters had a significant influence on the presence of
NASH in both cohorts combined and in separate (Table 2).
In the combined analysis of both cohorts the deviation in size between the subgroups was
taken into consideration for correct adjusting. After adjustment for origin the three miRNAs
122, 192 and 21 turned out to be highly significant co-variables in the logistic regression analy-
sis (OR 0.592/p = 0.001, OR 0.487/p = 0.002 and OR 0.309/p<0.0001, respectively) (Table 2).
In MOC patients, parameters of significant influence were miR-21 and the cellular apoptosis-
marker CK18-Asp396 (p 0.05). In SOC patients, the number of relevant parameters further
included miR-122 and miR-192, whereas CK18-Asp396 was not significant in this subgroup.
From these results, it appeared straightforward to combine expression of miRNA-122, -192
and -21 for further analysis with the aim of defining a combined score of individual miRNA
markers for non-invasive NASH diagnosis.
Fig 1. Relative detection profile of four investigated circulatingmicroRNAs. Pooled data from both study cohorts (SOC &MOC). Displayed microRNAs
show significant difference in detection between NASH patients and healthy controls. MicroRNAs -122 (A), -192 (B) and -21 (D) discriminate between bland
steatosis and NASH patients. For miR-223, this difference could only be detected in one cohort (SOC; S1 Fig). MicroRNA data is normalized with miR-103
and miR-425. (Displayed: Median + interquartiles-range; whiskers = quartiles).
doi:10.1371/journal.pone.0142661.g001
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OR is<1 despite of a higher expected risk, as it is calculated with Δ-Ct values which have an
inverse correlation to increasing miRNA counts.
Correlation of routine serum parameters and miRNA expression profiles
in circulation
In a next step detected miRNA profiles were correlated to available routine serum parameters
such as ALT and CK18-Asp396 fragments (Fig 3). As miR-122 and miR-192 showed a very
similar profile pattern in the different patient groups, their correlation was highly significant
(R = 0.83, p< 0.0001, Fig 3). Both had a significant and positive correlation with serum ALT
(miR-122: R = 0.53, p< 0.0001; miR-192: R = 0.45, p< 0.0001) (Fig 3). CK18-Asp396 fragment
levels increased with the development of bland steatosis and the progression to NASH (Fig 3,
S3 Fig). Again, a positive and significant correlation of CK18-Asp396 fragments to respective
miRNA levels has been observed (miR-122: R = 0.48, p< 0.0001; miR-192: R = 0.36, p<
0.0001) (Fig 3). For miR-21 a positive significant correlation could be shown to ALT level but
no correlation to CK18-Asp396 or other miRNAs could be determined (S1 Table). For miRs-
21, -122 and -192 profile levels were also correlated with single NAS parameters (degree of
steatosis, ballooning, lobular inflammation and fibrosis). A relevant correlation of all individual
miR levels could be detected in comparison to the degree of steatosis. Also, a significant corre-
lation of lobular inflammation to miR-21 and miR-122 could be found (S1 Table).
Diagnostic performance of routine serum parameters, CK18-Asp396
fragments and miRNA levels in circulation
As a final step, diagnostic performance of miR-122, -192 and -21 in a combination score com-
pared to routine parameters such as ALT and CK18-Asp396 fragments has been analyzed in
NAFLD patients.
A simplified scoring system has been developed dividing measured expression in both
patient groups by the median (applied cut-offs shown in S2 Table) and subsequently scoring a
Fig 2. Circulating MicroRNA profile in comparison to histological NAS score.MicroRNA detection profile is shown as delta Ct. Pooled patient groups
with NAS n.d.+ 0–2, 3+4 and 5+ could be significantly discriminated by lower delta Ct measures for miR-122 (A), miR-192 (B) and miR-21 (data not shown;
p = 0.025–0.0258).
doi:10.1371/journal.pone.0142661.g002
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lower or equal appearance with ‘0’ and a higher with ‘1’ finally summing up the results for all
three miRNAs to a total score from 0 to 3. Alternatively, a combination with CK18-Asp396
fragment levels was applied, scored by the same method as miRNA expression with a total
score from 0 to 4. To evaluate the diagnostic performance of this miRNA sum scoring, we per-
formed a multivariate ROC and AUROC and compared it to ALT and CK18-Asp396 frag-
ments alone (Fig 4).
Prediction with combined miRNA profiles showed an increase in AUROC compared to
ALT alone (AUROC = 0.77) with the same diagnostic performance as CK18-Asp396 fragments
(both AUROC = 0.81). Combination of these two predictors by applying a scoring system from
0–4 further increased the area under ROC by additional 0.02 (= ΔAUROC), to a value of 0.83
(Fig 4), which is showing a high sensitivity for the absence of steatohepatitis (score 0) and the
diagnosis of NASH (score 4) (S4 Fig).
Table 2. Binary logistic regression analysis.
SOC
OR Confidence Interval (95%) p-value
Age 1.049 0.995–1.106 0.076
Gender 1.517 0.458–5.020 0.495
BMI 0.995 0.935–1.060 0.887
CK18-Asp396 1.001 0.999–1.002 0.421
miR-122 0.526 0.332–0.834 0.006 **
miR-192 0.416 0.216–0.801 0.009 **
miR-223 0.556 0.306–1.010 0.054
miR-21 0.313 0.148–0.660 0.002 **
MOC
OR Confidence Interval (95%) p-value
Age 1.014 0.968–1.063 0.552
Gender 0.5 0.145–1.72 0.272
BMI 0.956 0.842–1.085 0.487
CK18-Asp396 1.008 1.001–1.014 0.021 *
miR-122 0.666 0.430–1.032 0.069
miR-192 0.584 0.299–1.143 0.117
miR-223 0.858 0.382–1.927 0.71
miR-21 0.302 0.112–0.814 0.018 *
SOC and MOC (adjusted for origin)
OR Confidence Interval (95%) p-value
Age 1.03 0.995–1.066 0.093
Gender 0.863 0.374–1.992 0.73
BMI 0.988 0.933–1.046 0.674
CK18-Asp396 1.002 1.000–1.003 0.09
miR-122 0.592 0.434–0.808 0.001 ***
miR-192 0.487 0.308–0.770 0.002 **
miR-223 0.643 0.402–1.029 0.066
miR-21 0.309 0.170–0.561 0.000 ****
*: 0,01 < p  0,05
**: 0,001 < p  0,01
***: 0,0001 < p  0,001
****: p  0,0001
doi:10.1371/journal.pone.0142661.t002
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Fig 3. Correlation between different circulatingmicroRNA levels and other serum parameters.MiR-122 and miR-192 showed a very similar profile in
the different patient groups; their correlation was highly significant (A). Correlation was also analyzed in comparison to the routine serum parameters ALT and
CK18-Asp396. MicroRNAs -122, and -192 could be positively correlated with ALT and CK-18 (B, C, E, F). CK18-Asp396 fragment levels increased with the
development of bland steatosis and the progression to NASH (D). Detailed results are displayed in S1 Table. Correlation between variables was calculated
using Spearman’s Rank correlation test.
doi:10.1371/journal.pone.0142661.g003
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The test result variable(s): Predicted probability has at least one tie between the positive
actual state group and the negative actual state group. Null hypothesis: true area = 0.5.
Discussion
Major differences for NAFL and NASH in the risk of progression to end stage liver disease,
decompensation and HCC development necessitate a reliable non-invasive risk assessment in
Fig 4. Diagnostic performance of microRNA level in circulation was evaluated bymultivariate receiver operating characteristic (ROC) in patient
group. Predictive potential of ALT (A) (AUROC: 0.77 / CI 95%: 0.685–0.854 / p: <0.001) and CK18-Asp396 (B) (AUROC: 0.81 / CI 95%: 0.733–0.837 /
p: <0.001) was evaluated, represented by calculated area under ROC (AUROC). MiR-122, -192 and -21 in a combination score showed comparable results
with CK18-Asp396 discrimination (C) (AUROC: 0.81/ CI 95%: 0.725–0.888 / p: <0.001). The best characteristics could be observed by combining the score
with CK18-Asp396 fragment level (D) (AUROC: 0.83 / CI 95%: 0.754–0.908 / p: <0.001) to differentiate between NAFL and NASH.
doi:10.1371/journal.pone.0142661.g004
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routine clinical practice. Currently no valid method to differentiate between NAFL and NASH
is available except liver biopsy with histological diagnosis. Therefore, the search for suitable
serum biomarkers is pursued with high priority.
We hypothesize that circulating miRNA profiles hold great potential to predict the presence
of NASH as serum biomarkers. Candidate miRNAs included miR-122 and -192, which have
been identified by previous studies as to be associated with NAFL and NASH [17]. Additional
candidate miR-21, which has been shown to be associated with clinically diagnosed but not
biopsy proven NAFLD [33]. MiR-223 appeared as another potential biomarker for NAFLD
progression since it has been shown to be significantly up-regulated in liver tissue of NASH
patients (unpublished data) and has been shown to be differentially expressed in serum of
HBV positive HCC patients [35].
MiR-122 represents the most abundant microRNA in adult human liver (approx. 70% of
total miRNAs) and has been associated with de novo lipogenesis and lipid trafficking [36, 37].
A significant increase of miR-122 in the serum of NASH patients has been identified with posi-
tive correlation to the stages of inflammation and fibrosis [37]. Li et al. described an inhibitory
effect of miR-122 on the stellate cell activation and collagen deposition within the liver indicat-
ing a link between decreased miR-122 and fibrotic liver damage [38]. In line with these obser-
vations, a decreased expression of miR-122 has been observed in liver tissue of patients
suffering from NAFLD [39]. Recently, Pirola et al. had shown increased miR-122 serum levels
with the manifestation of NASH [17]. Several studies have observed the decreased miR-122
expression within the liver and its increase in serum in the pathophysiological context of severe
liver disease and documented a correlation between hepatocyte destruction and miR-122
export [40–42]. Recently published data also suggested that elevated levels of miR-122 in the
circulation play a crucial role in regulation of genes involved in endothelial damage, as for
instance the L- arginine transporter SLC7A1 [17, 43, 44].
For miR-192 comparable data are scarce. MiR-192 has been shown to share a pri-miRNA
with miR-194 and to play a crucial role in diabetic nephropathy [45]. They are known to be
upregulated by TGFβ1 [45], a key fibrogenic cytokine in hepatic stellate cells. Recent data by
Pirola et al. indicating an increased miR-192 in liver tissue and serum of NAFL and NASH
patients, further underline the role of this miRNA in different pathologies within the metabolic
syndrome [17]. The present study confirms these observations indicating a significant correla-
tion of miR-122 and miR-192 to the manifestation of NASH [17]. Most importantly, signifi-
cant differences for both miRNAs between NAFL and NASH patients could be confirmed and
render these two as biomarker candidates.
MiR-21 has been associated with several diseases before and it was also one of the first
described oncomirs [46]. MiR-21 has also been identified as a potential diagnostic marker of
viral hepatitis [47, 48]. As a new finding in our study we could show that circulating miR-21
level is significantly increased in patients suffering from NASH compared to HC and NAFL
patients. An altered level in undifferentiated NAFLD has been shown before [33]. MiR-21 has
also been found elevated in the context of liver fibrosis and could be correlated with higher
fibrosis stages [49]. Although we do not detect such a correlation for the entire study popula-
tion we assume the differences in miR-21 expression between the NASH and NAFL group may
be at least partially reflected by increased fibrosis scores and fibroscan elasticities. The present
data now indicate that miR-21 is further increased in inflammatory states of fatty liver disease
since both cohorts showed a significant increase in NASH. The findings are in line with ele-
vated miR-21 in HCV infected serum and hepatocytes [48, 50] which also point to a role as a
marker for necroinflammatory activation in the context of viral infection.
An upregulation of miR-21 could be detected in hepatocytes after unsaturated fatty acid
treatment which leads to a specific binding of miR-21 to PTENmRNA thereby initiating its
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degradation [51]. This particular study mechanistically explains decreased PTEN expression in
high-fat diet treated rats and NAFLD patients and suggests miR-21 also as a key factor for the
progression from NASH to HCC [51].
MiR-192 and -122 could be significantly correlated with CK18-Asp396 and ALT levels indi-
cating that these miRNAs are released from hepatocytes during pathophysiological states asso-
ciated with cell membrane impairment. Previous data indicate an increase of miR-122 in
serum with apoptosis of hepatocytes caused by inflammatory damage of the liver [52] and
explain the positive correlation with the apoptosis marker CK18-Asp396 fragment. A new find-
ing here is the correlation between ALT- and miR-21 serum level. It can be hypothesized, that
these miRNAs generally show an earlier increase than ALT in NASH patients, as is has been
shown for miR-122 in the context of viral, drug- and alcohol-related liver disease [53, 54]. This
hypothesis is strengthened by the fact, that 25% of our NASH patients with predictive miRNA/
CK18-Asp396 score showed no abnormities in routine ALT level. The correlation between
mir-122 and -192 is bringing up the question for a potential link in miRNA processing and
regulation.
Our data on those two microRNAS are validated by the findings in a similar cohort Pirola
et al. investigated earlier [17]. As the authors already investigated the potential of single miR-
122 to predict NASH [17], the aim of our study consisted in combining potential microRNA-
and other biomarkers to increase the diagnostic performance in the discrimination of NASH
from lower risk NAFL patients. Tan et al. published in 2014 a panel of miRNAs suitable for the
discrimination of NAFLD patients against healthy controls but found no difference for the dif-
ferent disease states of fatty liver disease [19]. Focus of this study was on the diagnosis of
NASH patients within the entire group of NAFLD patients. Following this aim, for logistic
regression and further analysis all NAFLD patients (NAFL plus NASH) were included. Results
of our logistic regression analysis brought us to the conclusion to further analyse miR-122,
-192, and -21 as potential biomarkers candidates. As CK18-Asp396 fragments has been exten-
sively investigated as a biomarker candidate [10, 11, 14], we used this marker as a reference
together with serum ALT levels. Defining the median as critical threshold to discriminate a
‘lower risk’ from a ‘higher risk’ group for every single biomarker candidate a composite score
with and without CK18-Asp396 inclusion has been developed. In contrast to previous studies
[17], we found CK18-Asp396 fragment levels to have a higher prediction potential compared
to ALT shown in ROC analysis. Our combined scoring model had the same diagnostic perfor-
mance in the discrimination of NASH CK18-Asp396 fragment serum levels. Combining the
3-miRNA profiles panel with CK18-Asp396 fragments could further improve the diagnostic
performance as shown in receiver operating characteristics.
The outcome of our study bears high potential for future improvement of clinical routine,
particularly for early disease. Our findings hold the potential to develop a reliable serum bio-
marker panel to identify patients “at risk” for NASH and thereby decrease the currently almost
universal need of liver biopsies with potential complications for NASH diagnosis. Significant
differences in miRNA serum levels, detectable by a decrease in Ct values, in different NAS
groups together with a gradual increase starting with the earliest NAS stages fuel the assump-
tion, that early detection and in turn treatment could be optimized with the potential use of
miRNAs as candidate biomarkers.
Supporting Information
S1 Fig. Relative detection profile of four investigated circulating microRNAs in severely
obese cohort (SOC). Selected circulating microRNAs show significant difference in detection
between NASH and NAFL patients as well as NASH patients and healthy controls, respectively.
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MicroRNA data is normalized with miR-103 and miR-425. (Displayed: Mean + SEM).
(EPS)
S2 Fig. Relative detection profile of four investigated circulating microRNAs in moderate
obese cohort (MOC). Significant difference between NAFL and NASH patients could be
detected for miR-21. For microRNAs 122 and 192 a discrimination between NAFLD and
healthy controls was shown, whereas a significant difference between the different stages of
NAFLD could not be detected. MicroRNA data is normalized with miR-103 and miR-425.
(Displayed: Mean + SEM).
(EPS)
S3 Fig. Relative CK18-Asp396 fragment levels in moderate and severely obese cohort. In
independent cohorts an increased abundance could be detected with the development of bland
steatosis without further increase in NASH. (Displayed: Mean + SEM).
(EPS)
S4 Fig. Total number of patients scored with combined circulating microRNA
/CK18-Asp396 fragment level model. The majority of definite biopsy proven diagnosis for
NAFL and NASH are detected by scores 0 and 4 (sensitivity 91% and specificity 83%).
(PDF)
S1 Table. Correlation analysis with microRNA serum level.MicroRNA level in circulation
correlated with routine serum parameters ALT and CK18-Asp396 and with single NAS param-
eters (Steatosis, lobular inflammation, ballooning and fibrosis). Also miRNAs 122 and 192
have been correlated. Analysis is applied by Spearman’s rank correlation test.
(PDF)
S2 Table. Applied cut-offs for scoring model in both cohorts for miRNAs and
CK18-Asp396 fragment level. Scoring of miRNA profile was performed by separating their
expression in the entire NAFLD group by median, scoring ‘0’ for lower or equal values (lower
risk) and ‘1’ for higher values (higher risk).
(PDF)
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Objectives: The increasing prevalence of obesity in western countries causes an 
elevation of the incidence of non-alcoholic fatty liver disease (NAFLD). The 
pathophysiological background of NAFLD is still not totally explored. The aim of this 
study is to identify a possible regulatory function of selected miRNAs on gene 
expression and their potential role as functionally relevant mediators of fatty liver 
disease. 
Methods: In the study, expression of four miRNAs (21, 122, 223 and 638) was 
investigated in a human liver biopsy cohort (49 NAFLD patients and six healthy 
controls) via RT-q-PCR to evaluate differences in expression between patients with 
non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver (NAFL) and healthy 
controls. Potential microRNA target genes known to be relevant for metabolic 
changes were also investigated in this cohort. In parallel, free fatty acid treated 
hepatocytes were used to evaluate a possible functional relationship of miRNA and 
mRNA expression. 
Results: For all four microRNAs of interest, a differential regulation between NAFLD 
patients and healthy controls could be demonstrated; liver specific miR-122 showed 
also a distinct expression between NAFL and NASH. Among those, miR-638 was 
newly shown to be differentially regulated in the context of liver disease. Expression 
patterns could be validated for miR -223 and -638 in cultured hepatocytes. 
Conclusions: MiRNAs previously associated with metabolic or inflammatory 
pathways were newly assigned to either NAFL, NASH or both. These data from liver 
tissue imply a role of certain miRNAs as potential mediators in the progression from 
bland steatosis to steatohepatitis and also appear to be of high importance to define 
the origin of clinically relevant pathophysiological events in fatty liver disease. 
Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease 
in developed countries with a prevalence of 20 to 35% [1, 2]. Non-alcoholic fatty liver 
(NAFL) is defined as bland steatosis and must be distinguished from non-alcoholic 
steatohepatitis (NASH) which is characterized by inflammatory infiltrates, ballooning 
and necroapoptosis. 5% to 20% of NAFLD patients develop a progression from NAFL 
to NASH. This is of particular importance since the presence of NASH and/or 
advanced fibrosis has been associated with an increased overall mortality in these 
patients [3, 4]. 
NAFLD is often defined as the hepatic manifestation of the metabolic syndrome, 
which is associated with insulin resistance, obesity, and type II diabetes. However, its 
pathogenesis is complex and still not fully understood [5]. 
It has been demonstrated in the past, that cytokines and oxidative stress are playing 
a role in the development of steatosis and more severe liver damage, such as 
advanced fibrosis. The progression from NAFL to NASH is also associated with the 
progression of the metabolic syndrome; hence associations to pro-inflammatory 
processes and insulin resistance could be demonstrated [6]. The linkage between 
type II diabetes and obesity remains in the focus. Hyperinsulinemia is causing 
elevated levels of insulin-like factor 1 (IGF-1), cytokines and sex steroids [7]. Also in 
this context a relation between chronic inflammatory state and obesity has been 
shown accompanied with elevated levels of pro-inflammatory cytokines tumor 
necrosis factor alpha (TNFɑ) and interleukin 6 (IL6) [8, 9]. 
Since the discovery of microRNAs (miRNAs) in 1993 [10], scientists demonstrated a 
regulative function in various gene expression pathways. These small RNAs of 19 to 
23 nucleotides in total length regulate gene expression acting usually at 
posttranscriptional level. In majority (80%), their sequence is located in non-coding 
intronic sections of the genome [11, 12]. The outcome of several studies also 
reported a potential role of miRNA regulation in the pathophysiology of NAFLD [8, 13, 
14]. This has also lead to a number of approaches, to use alterations of miRNAs in 
circulation as non-invasive diagnostic tools [15, 16]. To define miRNAs involved in 
the progression and development of NAFLD is baring high potential for future 
therapeutic perspectives, as an inverse treatment with respective miRNAs or anti-
miRNAs (antagomirs) in affected tissues might lead to positive treatment responses 
[14, 17, 18]. 
Various genes involved in the pathogenesis of NASH have been described in the 
past, also in line with respective targeting miRNAs. These include three isoforms of 
sterol regulatory element-binding proteins (SREBPs) which are transcription factors 
with important roles in triglyceride and cholesterol synthesis [19, 20]. For SREBP1 
and 2 a regulatory role of miR-24 could be demonstrated in a murine study [8]. The 
cholesterol sensor liver X receptor (LXR) is involved in the metabolism and 
absorption of sterols. Yoshikawa et al. described their promoting role in the 
development of NASH by an indirect activation of SREBP-1c [21]. Joseph et al. 
described a direct involvement in regulation of lipid synthesis, by interacting with 
genes such as for instance fatty acid synthase (FASN) [22]. More relevant data to 
picture and connect miRNA expression and related transcript regulation is scarce.  
As miRNAs have been associated previously with metabolic or inflammatory 
pathways, the aim of this study was to define relevant miRNAs which could be newly 
assigned to either NAFL, NASH or both. Another goal was the functional assignment 
in central signaling pathways. The hypothesis of this study is that the selected four 
investigated miRNAs are playing a particular role in the development and progression 
of NAFLD and have a regulative function on the expression of FASN, PLIN5 (Perilipin 
5) and JUN (C-Jun). The identification of miRNAs of relevance as potential mediators 
in the progression from bland steatosis to steatohepatitis and also in the definition of 
the origin of clinically relevant pathophysiological events in fatty liver disease might 
be of high importance for potential treatment or diagnostic options within the future. 
  
Material and Methods 
 
Study design, patients and healthy controls 
In total, 49 NAFLD patients and 6 Healthy controls (HC) >18 years were enrolled 
between July 2007 and August 2014. All of them were characterized thoroughly at 
University Hospital of Zürich and the University Hospital Würzburg. All patients had 
histology proven NAFLD (28 NAFL/ 21 NASH) and were diagnosed with a non-
alcoholic fatty liver disease first by typical ultrasound findings with a sonographic 
NASH-score[23]. All liver samples were diagnosed by an experienced pathologist. 
Table 1 shows baseline parameters of NAFLD patients and controls. Subjects with 
significant alcohol consumption (females > 20g/day and males > 30g/day) and any 
pre-existing liver disease were excluded. Healthy control subjects were examined 
prior to living liver donation and had no evidence or history of liver pathology. 
Laboratory analysis showed no elevation for AST and ALT, as also no history of 
coronary heart disease, hypertension, valvular disease, any arrhythmia or systemic 
disease for inclusion in the study. 
The controls and patients were matched based on gender, and ethnicity. From all 
tissue samples, total RNA fraction was isolated for further analysis. All liver biopsies 
have been obtained either percutaneously or during bariatric surgery. 
The study was approved by the Würzburg University and Zürich cantonal ethics 
committee. Written informed consent was obtained from each patient prior to 




Liver tissue and cell culture samples; RNA isolation 
From routine liver biopsies a 5mm tissue cylinder was collected in cryotubes (TPP, 
2ml), directly snap frozen in liquid nitrogen and stored at −80°C until use. 25mg of 
tissue were cut from frozen biopsy sample and homogenized with pistil in 700 ml 
QIAzol lysis reagent (Qiagen). For functional assays cultured cells were harvested 
after 56 h with cell scratcher and directly taken up in 700 ml QIAzol lysis reagent. 
From homogenate, total RNA, including small RNAs was extracted with miRNeasy 
Mini kit (Qiagen) according to the Qiagen Supplementary Protocol for purification of 
small RNAs from tissue and cells, and finally eluted in a 50μl volume of nuclease-free 
water. RNAs were quantified by fluorometer and spectrophotometer (Nanodrop, 
Thermoscientific). 
 
MiRNA/mRNA candidate selection; cDNA-synthesis and 
RT-q-PCR 
Several miRNAs were defined as candidates of interest, as they have been reported 
to be associated with liver disease or other metabolic manifestations in present 
literature (miRs-21, -122, -223). MiR-122 is the most abundant miRNA and specific in 
liver tissue [24, 25]. MiRNAs -21 and -223 have been reported to be associated with 
NAFLD, hepatocellular carcinoma or type II diabetes [26-28]. MiR-638 was also 
included as it showed a significant difference between two small groups NAFL and 
NASH patients in a pilot study using an unbiased array approach (data not shown). 
Quantification of miRNA expression for candidate miRNAs was performed by RT-q-
PCR. cDNA transcription was performed by two different protocols: For three 
miRNAs (MiR-122, -21, -223), RNA (500ng) was reverse-transcribed in 20 µL 
reactions using the NCode™ Vilo™ miRNA cDNA synthesis kit (life technologies) 
according to user manual (Version A, 12 February 2009). The cDNA was diluted 1:10 
and amplified in 10 µL PCR reactions using Express SYBR GreenER™ miRNA RT-
q-PCR Kit (life technologies) according to user’s manual (Version A, 12 February 
2009). The amplification for single RT-q-PCR for each of the ten miRNAs was 
performed on 7900 HT real-time PCR instrument (Applied Biosystems) using specific 
designed miRNA primers (Microsynth, Switzerland) to quantify miRNA. For miR-638, 
TaqMan Small RNA Assays, MicroRNA Assays (TaqMan®) was performed. Reverse 
Transcription was done with TaqMan MicroRNA Reverse transcription Kit (life 
technologies), and for RT-q-PCR, Taqman Universal PCR Mastermix II (2x), no UNG, 
was used (all material life technologies) according to user’s manual (Version 
01/2011). RT-q-PCR for miR-93 (as intracellular reference miRNA [29-31]) was 
performed for both methods. 
Three gene transcripts of metabolic and inflammatory pathways were defined to be 
candidates of interest chosen by the selection criteria (i) potential target of the 
relevant miRNAs and (ii) pathophysiological relevance in liver metabolism. The 
candidate genes were FASN (encoding fatty acid synthase) and JUN (encoding c-
Jun N-terminal kinase); selected as they are potential targets of miR -21, -122 and -
223. PLIN5 (encoding perilipin 5) is a predicted target for the newly described miRNA 
638 and is known to be involved in lipid droplet accumulation [32]. Quantification of 
mRNA expression for candidate mRNAs was performed by RT-q-PCR with whole 
cohort in one run. cDNA transcription was performed by High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) according to manufacturer’s 
instructions (Vers. 11/2010). RNA (500ng) was reverse-transcribed in 20 µL 
reactions. The cDNA was diluted 1:10 and amplified in 10 µL PCR reactions using 20
✕ Gene Expression Assay and 2✕ Gene Expression Master Mix (both: TaqMan®) 
according to user’s manual (Version 11/2010). RT-q-PCR was performed on 7900 HT 
real-time PCR instrument (Applied Biosystems). mRNA data was normalized with 
human HPRT gene. 
 
Primer 
Primer for Express SYBR GreenER™ miRNA RT-q-PCR Kit (life technologies) were 
designed according to manufacturer’s manual (life technologies, Version A, 12 
February 2009), melting temperature was evaluated by Oligo Analyzer 3.1 (IDT, 
Iowa, USA) and oligo assembling was performed by Microsynth (Switzerland). 
 
miRNA Primer-Sequence T melt (°C) 
miR-122 GCC GCA ACG CCA TTA TCA CAC TAA ATA AAA AA 60 
miR-21 GCC CGT AGC TTA TCA GAC TGA TGT TGA A 60.1 
miR-223 CCC CTG TCA GTT TGT CAA ATA CCC CA 60.7 
miR-93 GCA AAG TGC TGT TCG TGC AGG TAG 60.7 
 
Cell culture 
Immortalized Human hepatocytes (IHH) were cultured in WilliamsE Medium (Sigma 
Aldrich), containing 10% FCS (TPP, Switzerland), 2mMol/L L-Glutamin (Sigma 
Aldrich), 100U/ml Penicillin/Streptomycin (Sigma Aldrich), 20mU/L Insulin solution 
and 50 nMol/L Dexamethason (Sigma Aldrich). Briefly, 5x105 human hepatocytes 
were plated in 6-well collagen I coated clear plates. After 24 hours, hepatocytes were 
treated with either the control medium (WilliamsE as described above), Vehicle 
control medium (control medium containing 0.25% Isopropanol) or medium 
containing oleic acid (Carl Roth, Germany) (control medium containing Isopropanol 
and oleic acid in concentrations 50, 100, 250, 500mM). Cells were cultured for 
another 32 hours before harvesting. All concentrations were applied in four 
independent assays. RNA isolation was done as described above. mRNA data is 
normalized with human HPRT gene. 
 
Statistics 
Statistical analyses and graphs were performed and created with Prism5 (GraphPad 
Software, La Jolla, CA).  
P-values < 0.05 were considered statistically significant (*< 0.05, **< 0.01, ***< 
0.001). Quantitative data were expressed as mean ± standard error of mean unless 
otherwise indicated. For relative miRNA expression, miR-93 expression was 
considered for normalization [30, 31]; 2-Δ Ct –method was used. To compare miRNA 
expression, Mann-Whitney U test was applied. Correction for multiple testing was not 
applied, as the focus of the study was rather exploratory.  
Results 
 
Baseline patient characteristics 
Data from 55 participants were included in the study (28 NAFL, 21 NASH, 6 HCs) 
(Table 1). The groups did not differ in age, sex, race/ethnicity, or alcohol intake. 
Patients with NASH and NAFL, had higher BMI than HCs. Liver transaminases, 
fasting glucose, triglycerides and total cholesterol were higher in patients than in 
HCs. For triglycerides and total cholesterol the values were higher in NAFL patients 
than in the NASH group. 
 
Expression data in whole cohort 
RT-q-PCR showed significant differences in expression patterns for all four miRNAs 
of interest.  
MiR -21 showed an increase in expression for NAFLD patients compared to controls 
(p= 0.0042 - 0.0053), however statistical significance was not obtained between the 
subgroups of NASH and NAFL (Fig. 1A).  
MiR-122, which has been demonstrated in the past [13] to be downregulated in 
NAFLD patients, could be validated in the investigated cohort, but also a significant 
differentiation between NAFL and NASH could be observed (p = 0.0256). MiR-223 
and -638 showed no differential expression between bland steatosis and 
steatohepatitis; however the expression showed a significant difference comparing 
NAFLD and healthy tissues (Fig.1C/D). 
MRNA expression  
The expression of the three target genes of interest was analyzed via RT-q-PC. For 
all three genes an upregulation could be observed (Fig. 2). FASN and JUN showed a 
significant expression difference in comparison to the healthy control group. 
However, an expression difference between NAFL and NASH could not be observed 
(Fig. 2 A/B). For PLIN5, a marginal difference could be obtained however without 
statistical significance (Fig. 2 C). 
 
Functional assays in cell culture 
In an in vitro assay, IHH cells were treated with free fatty acids (FFA) to simulate the 
condition of hepatic lipid accumulation and lipotoxicity. Different FFA concentrations 
were applied in independent assays. First, the expression of target miRNAs was 
measured via RT-q-PCR, to verify if similar expression patterns as in human samples 
could be obtained. MiRNA 223 showed an upregulation when comparing treated and 
untreated cells. Only in cells treated with FFA in high concentrations (250/ 500 mM) a 
significant difference could be observed (p = 0.0286) (Fig. 3A). The direction of 
regulation is corresponding to the human liver biopsy cohort. 
For miR-21, a downregulation could be observed, which stands in contrast to 
observations in the patient cohort on the first view. For the treatment with 100 and 
500 mM of FFA, this expression change was significant (p = 0.0286) (Fig. 3B).  
MiR-638 showed for all treatment conditions lower expression. However, a significant 
change could only be observed in treatment with the lowest concentration (50 mM) (p 
= 0.0286) (Fig. 3C). For miR-122, no change in expression could be observed in 
treated hepatocyte cultures (Fig. 3D). 
MRNA expression for the three genes of interest has also been determined in the 
same cell culture assays. JUN transcripts did not show any change in abundance in 
cells treated with high concentrations of FFA (250/ 500mM). A visible trend towards 
upregulation, comparable to the expression pattern in human tissue, could be 
observed in assays treated with low concentrations of FFAs but statistical 
significance could not be reached (p (100mM) = 0.13) (Fig 4A). 
Evaluation of FASN expression also showed no changes in assays treated with low 
concentrations of oleic acid. In the highest concentration a visible tendency of higher 
expression could be determined (p=0.2) (Fig 4B) which would be likewise as in 
patient cohort. 
For PLIN5 the expression pattern in cell culture showed the most constant increase 
depending on FFA concentration reaching a plateau with higher FFA concentrations 




As the development and progression of NAFL and NASH is not entirely understood 
on the functional level, the present study investigated the tissue expression of four 
miRNA candidates in healthy livers and the different stages of fatty liver disease. The 
exploratory approach included also an analysis of potential pathophysiologically 
relevant mRNA targets of these miRNAs and a first functional analysis in an in vitro 
model. 
MiR-21 was described to be one of the first oncomirs, hence a lot of its targets are 
known and described as tumour suppressor genes. Prominent examples would be 
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A (ANP32A), 
phosphatase and tensin homolog (PTEN) and SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, subfamily A member 4 [33, 34]. In this study, 
an upregulation in NAFLD patients could be detected. Similar changes could also be 
observed by Vinciguerra et al., who described an upregulation in hepatocytes after 
unsaturated fatty acid treatment, mediated by NF-κBp65/ mammalian target of 
rapamycin (mTOR)-complex. [35]. In contrast to this study, our observations show a 
downregulation of miR-21 in cultured hepatocytes. A possible explanation could be 
the longer incubation with oleic acid in our approach. As Vinciguerra et al. described 
a fast increase of miRNA expression after 24 hours with low concentrations of FFA 
(50mM), a fast alteration in the beginning followed by a decrease caused by the 
binding to PTEN transcripts can be suspected [35] after 32 hours. Also possible 
would be an intracellular mechanism setting the miRNA free during cell degradation 
in the extracellular matrix as it is known for miR-122 [13, 25]. The presented results 
further underscore potential of miR-21 as a key mediator of the metabolic syndrome 
and NAFLD.  
MiRNA 122 is the most abundant miRNA within the liver and was also the first with a 
functional link to lipid homeostasis and metabolism [36]. Cheung et al. showed a 
highly significant downregulation of miR-122 in NASH patients [13]. This particular 
downregulation can also be assessed from the presented data, whereas in the 
present study an additional significant difference between NAFL and NASH patients 
could be detected. Cheung et al. further assessed the effects on its targets by 
overexpression and silencing in an in vitro study and observed a number of effects on 
target genes in protein translation, cell proliferation, inflammation, apoptosis, 
oxidative stress and metabolism. The functional impact on lipid metabolism caused 
by decreased miR-122 [13] contributed to the hypothesis that these 
pathophysiological effects could be mediated by an upregulation of the miR target 
genes JUN (inflammation) and FASN (lipogenesis). As predicted, an upregulation of 
miR-122 could be observed in human liver tissue of NAFLD patients but could not be 
replicated in the IHH model (Fig. 4). The significant difference in miRNA expression 
between NAFL and NASH patients could not be seen at the level of potential mRNA 
target transcripts. An explanation would be the fact that often several miRNAs are 
targeting one gene transcript [37]. Nevertheless, the correlation of the expression 
pattern between miR-122 and its mRNA targets in human liver tissue might be 
another hint for a regulative function. An in-depth evaluation of miRNA and mRNA 
expression, which is already subject of mathematical remodeling analyses in the field 
will bring new light in the regulative link between miR-122 and its targets genes.  
MiR-223 has been investigated not only in the context of hepatocellular and 
colorectal carcinoma [38, 39] but also regarding cholesterol uptake and homeostasis 
[40, 41]. However, it has not been investigated in human fatty liver disease to date. In 
this study an upregulation of the miRNA could be observed in the human study 
cohort and also in the cultured hepatocyte model. These results are in full 
accordance with a study conducted by Shpyleva et al. showing an altered hepatic 
expression in a rodent model of fatty liver disease[42]. The fact that miR-223 is also 
targeting the investigated genes JUN and FASN is another example for the fact the 
gene expression is not only regulated by one particular miRNA [37]. 
The newly described miRNA 638 has also not been investigated in the context of 
metabolic manifestations before at all. It came into the focus of interest when it 
showed a different regulation in a pilot study comparing two groups of NAFL and 
NASH patients. Also, one of its predicted targets is perilipin5 (PLIN5), a member of 
the Perilipin family which is encoding for the lipid storage droplet protein5 (LSDP5). 
Members of this protein family are essential for coating intracellular lipid storage 
droplets as well as their protection from lipolytic degradation[32]. The prevention from 
lipolysis is a crucial step in the development of hepatocellular steatosis. The 
expression of perilipins is highly abundant to adipocyte and steroidogenic cells, as for 
instance hepatocytes [43-45]. In the extended context of liver diseases, there is no 
relevant data existing on miR-638, until very recently Kumar et al. showed an antiviral 
potential of the miRNA in the context of HBV infections [46]. Other studies showed 
different regulations in colorectal cancer patients [47, 48] but lacking a clarification of 
its functional pathways. In this study, however, a difference in expression within 
different stages of NAFLD could not be validated. Although a clear downregulation in 
patients compared to controls could be observed, a similar behavior appeared also in 
cultured hepatocytes treated with FFA. The clear significant effect on PLIN5 was 
lacking in the tissue cohort, even when direction of regulation was as expected. In 
IHH cells this effect was significant for treatment with low concentrations of FFA (50-
100mM), which might be evidence for a dependence on the degree of steatosis. The 
verification of these predicted target genes, suggesting a regulatory role in the 
context of metabolic manifestations or a potential contribution to NAFLD development 
represent one goal of further investigations within this field. 
The results of this study are giving clear evidence, that the four miRNAs of interest 
are playing an important regulatory role in the context of NAFLD in general and in 
part even discriminate bland NAFL from NASH. The present data at least give a clear 
hint on their influence on potential inflammatory and lipogenic target genes. Only a 
final analysis also considering a broad miRNA/mRNA expression data overview 
based on mathematical correlation modeling will bring light in the multi-regulated 
miRNA/transcript conjunction. Future unbiased studies, such as an ongoing array 
study in our group will allow such calculations and contribute to the investigation of 
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Tables and figures 
 
Table 1:  
Tab. 1: Full Cohort  
n=55 HC (n=6) NAFL (n=28) NASH (n=21) 
Sex (m/f)  3/3 12/16 10/11 
Age 37.2 ± 12.4 46.0 ± 12.8 49.4 ± 11.0 
BMI 23.7 ± 4.9 36.3 ± 11.4 34.9 ± 11.0 
Fasting glucose [mmol/l] 5.1 ± 0.2 5.9 ± 1.5 7.6 ± 3.9 
Triglycerides [mmol/l] 0.7 ± 0.2 4.1 ± 4.8 2.5 ± 1.5 
Cholesterol total [mmol/l] 4.7 ± 0.9 6.8 ± 3.9 5.1 ± 1.6 
AST [U/l] 22.8 ± 4.7 46.2 ± 27.7 64.4 ± 31.9 
ALT [U/l] 23.5 ± 18.1 68.9 ± 44.1 101.7 ± 61.0 
 
Baseline participant characteristics in NAFLD- and control cohort. Values given 
are expressed as mean ± standard deviation unless indicated differently. 
 
Figure 1:  
 
Relative expression patterns of four investigated microRNAs. Pooled data from 
full study cohort. Displayed microRNAs show significant difference in detection 
between NASH/NAFL patients and healthy controls. MicroRNA -122 (b) discriminates 
between bland steatosis and NASH patients. MicroRNA data is normalized with miR-









Relative expression patterns of three investigated gene transcripts. Pooled data 
from full study cohort. Displayed genes JUN (A) and FASN (B) show significant 
difference in detection between NASH/NAFL patients and healthy controls. PLIN5 
shows expected direction of regulation without reaching level of significance (C) (p= 









Relative expression patterns of four investigated microRNAs in cultured 
hepatocytes (IHH). Pooled data from four independent assays. 5x105 human 
hepatocytes were treated after 24 hours with control medium, vehicle control medium 
or medium containing oleic acid (concentrations 50, 100, 250, 500mM). Cells were 
cultured for another 32 hours before harvesting. Three of four displayed microRNAs 
show significant difference in expression between treated cells and controls 
(untreated). MicroRNA -122 (D) shows no expression difference in all assays. 
MicroRNAs -223 (A) and -21 (B) show a relevant difference only in assays treated 
with high concentrations, whereas a significant change for miR-638 could only be 
detected in the lowest concentration (50 mM; B). MicroRNA data is normalized with 





Fig. 4: Relative expression patterns of three investigated gene transcripts in 
cultured hepatocytes (IHH). Pooled data from four independent assays. 5x105 
human hepatocytes were treated after 24 hours with control medium, vehicle control 
medium or medium containing oleic acid (concentrations 50, 100, 250, 500mM). Cells 
were cultured for another 32 hours before harvesting. For PLIN5 a significant 
difference in expression could be detected between treated cells (100mM) and 
controls (untreated) (C). mRNA data is normalized with human HPRT gene. 






The prevalence of NAFLD represents a rising health problem in Western countries. 
Major differences for NAFL and NASH in the risk of progression to end stage liver 
disease, decompensation and HCC development necessitate a reliable non-invasive 
risk assessment in routine clinical practice as also the pathophysiology of the 
disease is not entirely clear. The sole fact, that there is a differential expression of 
some miRNAs in the serum of NAFLD patients is not new97, 278. Also an involvement 
of miRNAs in the different states of the disease within liver tissue samples could be 
demonstrated139. However, clarification of the functional mechanisms of miRNAs 
within the pathophysiology of the disease is often missing. Also a clear separation of 
NAFL and NASH patients is a major weakness in most previous studies. At the end, 
miRNAs and other potential serum biomarkers have been investigated, but a 
candidate showing a specific and satisfying performance as diagnostic biomarker 
could not be defined14. 
The results presented in this work describe miRNAs’ miR-192 and miR-122 role as 
discriminating serum biomarkers. These miRNAs have been observed before to 
have a prognostic potential in the discrimination between NAFL and NASH97; which 
could be validated in different cohorts. Furthermore, miR-21 could be described as a 
new miRNA candidate significantly upregulated in serum of NASH patients only, with 
the conclusion to be a relevant marker for NASH diagnosis. As miR-21 has been 
investigated to play a role in the context of more than one disease240, obviously a 
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combined model was designed, pooling the expression data of the three noted 
miRNAs with CK-18 fragment level. A simplified scoring model was evaluated for its 
diagnostic specificity and efficiency in NASH detection in a multivariate analysis. 
Also, an exploratory approach should expose whether miRNAs have differential 
expression patterns in liver tissue of NAFL and NASH patients and healthy controls. 
This part of the study was aiming to detect potential functional mechanisms within 
the progression from healthy liver into bland steatosis and further into the state of 
inflammatory manifestation on four candidate miRNAs. Within the study, expression 
data of a human biopsy cohort consisting of NAFL and NASH patients and healthy 
liver samples was compared. In parallel, the corresponding mRNA expression profile 
of three regulative target genes of analyzed miRNAs, all described to be highly 
relevant in liver metabolism and inflammation was generated; with the implication to 
bring new light in respective direct regulative interaction of these miRNAs. First 
approaches to analyze pathophysiological consequences on central metabolic and 
inflammatory pathways have been undertaken and build the groundwork for further 
functional assays in an in vitro model. 
 
5.1 Rationale of the study design 
In one part of this study the focus is on the diagnostic potential of miRNAs in fatty 
liver disease, respectively in the discrimination of NAFL from NASH. This could be 




independent cohorts consisting of NAFL and NASH patients and healthy controls, 
each. Importantly, for a clear differentiation between NAFL and NASH, all patients 
included have previously undergone a liver biopsy which was examined by an 
experienced pathologist. The panel consisted of miRNAs recently published to be 
differentially regulated between NAFL and NASH patients97 as well as of miRNAs 
which came to the focus of interest due to differential regulation in liver tissue. As the 
two cohorts were assembled in different degrees of obesity (moderate and morbid 
obesity), the study had more than one aim. The first was to verify miRNA expression 
presented in current literature in general, but also to see whether the expression is 
dependent on the degree of obesity, which has not been observed before. The 
second aim was to investigate the role of selected miRNAs, which showed 
detectable expression patterns in hepatic tissue, as potential biomarkers for the 
discrimination of NASH patients in serum. As more than one miRNA showed a 
significant difference in appearance between NASH and NAFL patients, the 
assessment of a simplified combined scoring system was self-evident. When the 
combination of miRNA levels showed no improvement in comparison to established 
prediction factors, the miRNA data was combined with measurements of CK-18 
fragment level. CK-18 is an apoptosis biomarker which holds potential92, 93, but is not 
yet recommended as solid marker for differentiation between NAFL and NASH by 
current clinical guidelines14, 92, 93. The resulting data was evaluated on its diagnostic 
efficiency and specificity in a multivariate receiver operating characteristic (ROC) 
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and compared to other existing prognostic markers, as for instance the altered levels 
of liver transaminases.  
In the functional approach applied within this work in liver tissue, expression of four 
miRNA candidates was investigated in a human study cohort. A crucial step was the 
initial critical evaluation of patient data to define groups with the highest possible 
level of homogeneity.  
Based on the fact that miR-122 is the most abundant and frequently investigated 
miRNA within the context of liver diseases203, it was included as a candidate of 
interest. Our motivation here was to investigate a well-established target for 
verification but also one which still bears a high potential for the detection of new 
regulatory mechanisms. 
In parallel - following the aim of this study to identify functional mechanisms of 
respective miRNA - total RNA of patients included in the same study cohort which 
was utilized for miRNA quantification was evaluated to obtain expression data of 
three target gene candidates.  
To follow this exploratory functional approach, human liver cell lines were treated 
with FFA, simulating the conditions of a deposition and accumulation of lipid 
droplets. Immortalized human hepatocytes (IHH) were chosen to receive 32 hours 
FFA treatment to induce ‘steatotic’ conditions. The first aim of establishing this 
model was the verification of expression patterns of miRNAs and mRNAs observed 




expression is representing the groundwork for further investigations to proof and 
demonstrate functional hypotheses, for instance via miRNA knockdown and 
overexpression. 
 
5.2 Summary of results 
The part of the study investigating the diagnostic role of miRNAs in NAFLD, the 
obtained results can be summarized as following: selected microRNAs’ expression 
levels were analyzed in serum of two independent human patient and control 
cohorts; one in a morbid and one in a moderate obese condition. MiRNAs 122 and 
192 have been identified before to be differentially expressed in NAFL and NASH 
patients97. Our results could validate these results; however we could observe a 
difference between the two cohorts, suggesting an influence of body mass on 
miRNA regulation. As a new finding, we could observe a significantly elevated 
expression of miR-21 in NASH patients, exclusively. The miRNAs expression was 
correlated among one another, presenting an interesting correlation between miR-
122 and miR-192. The correlated expression of miRNAs to other potential prognostic 
NAFLD biomarkers (ALT and CK-18 fragments) suggested promising parallels. A 
binary logistic regression model was used to evaluate the contribution of miRNA 
expression on NAFLD progression (NAFL to NASH). To combine the relevant 
parameters, a simplified scoring model was designed, pooling miRNA- and CK-18-
fragment levels. The diagnostic performance was evaluated by using receiver 
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operating characteristics (ROC) and showed an improvement in comparison to score 
parameters in exclusive use and to other prognostic markers. 
In the part of the study undertaken in human liver tissue we could demonstrate 
differential regulation of four microRNAs in the context of NAFLD: MiR-21, -223 and 
-638 showed alterations in comparison of patients to healthy controls. For miR-122, 
an additional significant difference could also be detected comparing NAFL and 
NASH patients. 
In concern of the evaluation of the total RNA in hepatic tissue of patients, the 
obtained results are the groundwork to generate a broad overview of mRNA 
expression within the different stages of NAFLD. Future unbiased studies, such as 
an ongoing array study will allow such calculations and contribute to the 
investigation of further functional miRNA/mRNA regulatory relationships in the 
pathogenesis of NAFLD. In mathematical and statistical network analysis, pathway 
analysis and regulation models are going to be generated, which will give a broad 
overview on miRNA dependent pathway regulation in the context of NAFLD 
progression. 
For advanced functional analysis an in vitro assay could be established, simulating 
the conditions of hepatic fat accumulation. A change of miRNA expression 
comparable to patient data could be detected for miR-21, -223 and -638. 
As four miRNAs were in the focus of further interest, the expression patterns of 




also investigated in liver tissue as well as in cultured cells. For miR of interest 638 a 
similar expression in hepatic tissue and cultured cells could be observed, the effect 
on its potential target gene PLIN5 could not be fully correlated: whereas in IHH cells 
an inverse correlation of expression was obtained, in liver tissue statistical 
significance could not be shown. For JUN and FASN, the expression data detected 
in vivo and in vitro was highly comparable: A higher rate of detected transcripts in 
patients and in FFA treated cells could be observed in comparison to healthy 
controls and untreated cells. 
 
5.3 MiRNAs as potential diagnostic markers in NAFLD 
The prevalence of NAFLD represents a rising health problem in western countries. 
As currently no valid non-invasive method to differentiate between NAFL and NASH 
is available, and liver biopsies are still associated with elevated risk and cost the 
search for suitable serum biomarkers is pursued with high priority. 
In the studies we have undertaken, miRNA expression with regard to their potential 
to predict the presence of NASH as serum biomarkers were in the focus of interest. 
The investigation of a panel of miRNAs and their appearance in serum brought new 
relevant findings for three of those candidates: MiR-122, -192 and -21. 
Liver specific miR-122 has been associated with de novo lipogenesis and lipid 
trafficking235, 236. Also, a significant increase of miR-122 in the serum of NASH 
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patients has been identified with positive correlation to the stages of inflammation 
and fibrosis235. The inhibitory effect of miR-122 on the stellate cell activation and 
collagen deposition within the liver described by Li et al. is indicating a link between 
decreased miR-122 and fibrotic liver damage237. The analysis of human liver tissue 
showed a decreased expression of miR-122 in patients suffering from NAFLD139. On 
the serum level, Pirola et al. had shown an increased miR-122 appearance with the 
manifestation of NASH97 as previously described for several other chronic liver 
diseases279, 280. The data this work is based on, obtained from tissue and serum 
could validate the described observations: An inverse correlation of miR-122, with a 
downregulation in liver tissue and its increased appearance in serum. The molecular 
basis of this observation is a described correlation between hepatocyte destruction 
and miR-122 export142, 281, 282. 
MiR-192 is a miRNA scarcely investigated in the context of NAFLD progression. It is 
known to be upregulated by TGFβ1238, a key fibrogenic cytokine in hepatic stellate 
cells. In a study, already mentioned in respect to miR-122, Pirola et al. observed an 
increased miR-192 level in serum of NAFL and NASH patients, also suggesting a 
role of this miRNA in different pathologies within the metabolic syndrome97. 
The results of our studies could confirm the observations of Pirola et al.97, indicating 
a significant correlation of miR-122 and miR-192 to the manifestation of NASH. Most 
importantly, significant differences for both miRNAs could be confirmed between 
NAFL and NASH patients and render these two as biomarker candidates. An 




our cohort suffering from morbid compared to moderate obesity. In moderate obese 
patients, in spite of consistent direction of effects, statistical significance was not 
obtained. These observations might suggest a regulation of miR-122 and -192 
dependent on the degree of obesity. 
MiR-21 has been associated with several diseases before; a fact which has been 
already analysed critically in respect to its potential use as a prognostic marker240. It 
was also one of the first described oncomirs245. The new finding from this work now 
is a significant upregulation of miR-21 exclusively in patients suffering from NASH. 
The present data now indicate that miR-21 is further increased in inflammatory 
states of fatty liver disease since no impact of obesity status of patients was 
observed. 
The positive correlation of miR-192 and -122 to CK-18 fragments and ALT levels 
indicate a release of these miRNAs by hepatocytes during pathophysiological states 
associated with cell membrane impairment. Roderburg et al. describes the increase 
of miR-122 in serum with apoptosis of hepatocytes caused by inflammatory damage 
of the liver283 which might explain the positive correlation with CK-18 fragment 
levels, a described marker for hepatic apoptosis. Another new finding obtained from 
our study is the positive correlation between serum miR-21 expression and ALT 
level. These observations lead us to the hypothesis, that these miRNAs generally 
show an earlier increase than serum ALT in NASH patients; an observation which 
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has already found to be an advantage for miR-122 in the context of viral, drug- and 
alcohol-related liver disease222, 284. 
The aim of our study consisted in combining potential microRNA- and other 
biomarkers to increase the diagnostic performance in the discrimination of NASH 
from lower risk NAFL patients. Logistic regression analysis brought us to the 
conclusion to further analyse miR-122, -192, and -21 as potential biomarkers 
candidates. The former extensive investigations of CK-18 fragments as a biomarker 
candidate brought us to the decision to include its appearance as a reference 
together with serum ALT levels into our considerations14, 92, 93. In a simplified 
composite score model, the median was defined as critical threshold to discriminate 
a ‘lower risk’ from a ‘higher risk’ group for every single biomarker candidate. We 
found CK-18 fragment levels to have a significantly higher prediction potential 
compared to ALT shown in ROC analysis, which exceeds the minor predictive 
values in the existing literature97. The newly developed miRNA scoring system 
showed the same diagnostic performance in the discrimination of NASH as CK-18 
fragment serum levels. Finally, the combination of the 3-miRNA expression panel 
with CK-18 fragments could even further improve the diagnostic performance.  
In respect to the future impact of our observations, it has to be mentioned that 25% 
of miRNA/CK-18 detected NASH patients had normal ALT, which is also 
strengthening our hypothesis made earlier concerning an earlier diagnosis via 




Serum miRNAs have been proposed as attractive diagnostic tools because of their 
minimal invasive nature and high stability in patients’ serum114. The described 
results from our study are a promising step in the development of a reliable serum 
biomarker panel to identify patients “at risk” for NASH and thereby decrease the 
currently almost universal need of liver biopsies with potential complications86. 
 
5.4 Role of MiRNAs in the pathophysiological context of NAFLD 
The development and progression of NAFL and NASH is not entirely understood on 
the pathophysiological level. The focus of the second study described in this work 
(see 4, Second manuscript) was laid on the expression of four miRNAs in either 
healthy livers and in different stages of fatty liver disease. This exploratory approach 
included also an analysis of regulative mRNA targets of these miRNAs and a first 
functional analysis in a cell culture model. 
MiR-21 showed an upregulation following the onset of NAFLD in the liver biopsy 
cohort. This behaviour could also be observed by Vinciguerra et al., who described 
an upregulation in hepatocytes after unsaturated fatty acid treatment, mediated by 
NF-κBp65/ mammalian target of rapamycin (mTOR)-complex. The determined 
mechanism was a specific 3’- UTR binding of miR-21 to the PTEN messenger 
transcript, initiating its degradation247. Our observations in cultured hepatocytes 
stand on the first sight in contrast to these findings described in the literature. They 
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show a downregulation of miR-21 in the in vitro model. A possible explanation could 
be the longer incubation with oleic acid in our approach. As Vinciguerra et al. 
described a fast increase of miRNA expression after 24 hours with low 
concentrations of FFA, we suspect a fast alteration in the beginning followed by a 
decrease caused by the binding to PTEN transcripts247 after 32 hours. Also possible 
would be an intracellular mechanism setting the miRNA free during cell degradation 
in the extracellular matrix as it is known for miR-122 139, 235. Not only the results 
obtained in this work show the enormous potential of miR-21 as a key mediator of 
MetS and NAFLD and suggest it to remain in the focus of scientific investigation178, 
249, 250. 
The important role of miR-122 has been addressed earlier in this work. Cheung et al. 
described a highly significant downregulation of miR-122 in NASH patients139. This 
particular downregulation could be validated in the present study (4, Second 
manuscript). In addition to the validation of these results a significant difference 
between NAFL and NASH patients could be detected. Cheung et al. could describe 
a number of effects in the field of protein translation, cell proliferation, inflammation, 
apoptosis, oxidative stress and metabolism. The knowledge of an altered lipid 
metabolism caused by decreased miR-122139 lead us to the hypothesis that 
functional regulation could be expressed by an upregulation of the miR target genes 
JUN (inflammation) and FASN (lipogenesis). As predicted an upregulation of miR-
122 could be observed in human liver tissue of NAFLD patients but could not be 




between NAFL and NASH patients could not be detected at the level of potential 
mRNA target transcripts. An explanation would be the fact that often numerous 
miRNAs are targeting one single gene transcript at the same time with interfering 
effects285. Nevertheless, the correlation of the expression pattern between miR-122 
and its mRNA targets in human liver tissue might be a hint for a regulative 
interaction. 
MiR-223 was not only in the focus of interest in the context of hepatocellular and 
colorectal carcinoma in the past253, 286 but also regarding cholesterol uptake and 
homeostasis252, 287. However, it has not been investigated in human fatty liver 
disease to date. As elaborately described in chapter 4, an upregulation of the miRNA 
could be observed in the human study cohort as also in the cultured hepatocyte 
model. These results are strengthened by the results of a study conducted by 
Shpyleva et al. describing an altered hepatic expression in a rodent model of fatty 
liver disease251. The fact that miR-223 is also targeting the investigated genes of 
interest JUN and FASN is another example for the fact the gene expression is not 
only regulated by one particular miRNA285. 
The rather newly described miR-638 has not been investigated in the context of 
NAFLD and MetS at all. It came into the focus of interest when it showed a different 
regulation in a pilot study comparing groups of NAFL and NASH patients 
(unpublished data). Of further importance, one of its predicted targets is perilipin5 
(PLIN5), an essential mediator within the pathway of coating intracellular lipid 
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storage droplets as well as their protection from lipolytic degradation267. The 
prevention from lipolysis is a crucial step in the development of hepatocellular 
steatosis. The expression of perilipins is highly abundant to adipocyte and 
steroidogenic cells, as for instance hepatocytes268-270. In the extended context of 
liver diseases, there was no relevant data existing on miR-638, until very recently 
Kumar et al. showed its antiviral potential in the context of HBV infections254. Other 
studies showed different regulations in colorectal cancer patients255, 256 but were 
lacking a final clarification of the underlying functional pathways. In this work the 
expected difference in expression within different stages NAFL vs. NASH could not 
be validated. However, a clear downregulation in the whole group of NAFLD patients 
compared to controls could be observed and a similar behavior appeared also in 
FFA treated cultured hepatocytes. In IHH cells a significant effect on PLIN5 was 
observed for treatment with low concentrations of FFA, which might be evidence for 
a dependence on the degree of lipid storage. This clear effect on PLIN5 was lacking 
in the tissue cohort, even though direction of regulation was as expected. The 
verification of these predicted target genes, suggesting a regulatory role in the 
context of metabolic manifestations or a potential contribution to NAFLD 





6 CONCLUDING REMARKS AND OUTLOOK 
In the presented studies, we could underline the important role miRNAs are playing 
in the pathophysiology and the diagnostic context of NAFLD. 
The obtained findings concerning the development of a reliable serum biomarker for 
the identification of NASH patients bear high potential for future improvement of 
clinical routine, particularly for early disease detection. The conclusion on the 
histological state of the liver presented by a non-invasive method fuel the 
assumption, that early detection and in turn treatment could be optimized by the use 
of miRNAs as additional biomarkers. The final establishment as a solid marker can 
only be obtained in multicentre studies with high numbers of enrolled patients. 
The higher expression of miR-21 in NASH patients’ serum leaves room for further 
investigation. An exclusive upregulation in this particular group is suggesting a 
potential role in the manifestation of the inflammatory state of the disease. As an 
upregulation of the miRNA could be also detected in liver tissue, a NASH specific 
release in the serum can also be suggested to be investigated with high priority. Also 
speculations may be allowed about a potential role in cell-cell communication. The 
high correlation of miR-122 and -192 in patient sera fuel the assumption about a 
potential link in regulation and leave space for further studies. 
Together with preclinical functional studies the obtained results considering the four 
microRNAs differentially expressed in liver tissue of NAFLD patients and healthy 
controls give a clear hint on the high importance of miRNA regulation in the 
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pathophysiology of NAFLD. The newly described discrepancy of miR-122 
expression in NAFL and NASH patients calls for further investigations in larger 
patient cohorts. An in-depth evaluation of miRNA and mRNA expression should 
bring new light in the regulative link between miR-122 and its targets genes.  
Further planned activities within this field would be the complete analysis and 
evaluation of two already performed broad expression data assays investigating the 
miRNA and mRNA expression in the liver tissue of NAFLD patients on an unbiased 
basis. The obtained data of both assays is already subject of mathematical network 
and correlation modelling, creating a broad insight into regulation of NAFLD 
progression in liver tissue. With this in silico approach a description of the relation 
between potential regulators and their respective targets can be achieved. The 
calculated alterations in pathway processing represent the groundwork of further 
functional assays in an in vitro model upon availability. 
The results of this work are giving clear evidence, that the investigated miRNAs are 
playing an important regulatory role in the context of NAFLD and give a hint on their 
influence on potential target genes. A final analysis also considering the full 
unbiased miRNA/mRNA expression assay data will bring light in the multi-regulated 
miRNA/transcript conjunction. Taking the outcome of these upcoming calculations 
together with the results presented within this work will build the essential basis for 
the final functional proof of the essential functional and pathophysiological role of 
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